Parallel	O
Analysis	O
of	O
mRNA	O
and	O
microRNA	O
Microarray	O
Profiles	O
to	O
Explore	O
Functional	O
Regulatory	O
Patterns	O
in	O
Polycystic	B-DS
Kidney	I-DS
Disease	I-DS
:	O
Using	O
PKD	B-DS
/	O
Mhm	O
Rat	B-OG
Model	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
HD	O
NG	O
.	O

Performed	O
the	O
experiments	O
:	O
HD	O
.	O

Analyzed	O
the	O
data	O
:	O
HD	O
CS	O
AK	O
PP	O
.	O

Wrote	O
the	O
paper	O
:	O
HD	O
NG	O
.	O

Autosomal	B-DS
polycystic	I-DS
kidney	I-DS
disease	I-DS
(	O
ADPKD	B-DS
)	O
is	O
a	O
frequent	O
monogenic	O
renal	B-DS
disease	I-DS
,	O
characterised	O
by	O
fluid	O
-	O
filled	O
cysts	B-DS
that	O
are	O
thought	O
to	O
result	O
from	O
multiple	O
deregulated	O
pathways	O
such	O
as	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
that	O
regulate	O
the	O
expression	O
of	O
many	O
genes	O
associated	O
with	O
such	O
biological	O
processes	O
and	O
human	B-OG
pathologies	O
.	O

To	O
explore	O
the	O
possible	O
regulatory	O
role	O
of	O
miRNAs	O
in	O
PKD	B-DS
,	O
the	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
rat	B-OG
,	O
served	O
as	O
a	O
model	O
to	O
study	O
human	B-OG
ADPKD	B-DS
.	O

A	O
parallel	O
microarray	O
-	O
based	O
approach	O
was	O
conducted	O
to	O
profile	O
the	O
expression	O
changes	O
of	O
mRNAs	O
and	O
miRNAs	O
in	O
PKD	B-DS
/	O
Mhm	O
rats	B-OG
.	O

1	O
,	O
573	O
up	O
-	O
and	O
1	O
,	O
760	O
down	O
-	O
regulated	O
genes	O
were	O
differentially	O
expressed	O
in	O
PKD	B-DS
/	O
Mhm	O
.	O

These	O
genes	O
are	O
associated	O
with	O
17	O
pathways	O
(	O
such	O
as	O
focal	O
adhesion	O
,	O
cell	O
cycle	O
,	O
ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O
,	O
DNA	O
replication	O
and	O
metabolic	O
pathways	O
)	O
and	O
47	O
(	O
e	O
.	O
g	O
.,	O
cell	O
proliferation	O
,	O
Wnt	B-GP
and	O
Tgfβ	B-GP
signaling	O
)	O
Gene	O
Ontologies	O
.	O

Furthermore	O
,	O
we	O
found	O
the	O
similar	O
expression	O
patterns	O
of	O
deregulated	O
genes	O
between	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
rat	B-OG
and	O
human	B-OG
ADPKD	B-DS
,	O
PKD1L3	O
/	O
L3	O
,	O
PKD1	B-GP
−/−,	O
Hnf1α	B-GP
-	O
deficient	O
,	O
and	O
Glis2lacZ	O
/	O
lacZ	O
models	O
.	O

Additionally	O
,	O
several	O
differentially	O
regulated	O
genes	O
were	O
noted	O
to	O
be	O
target	O
hubs	O
for	O
miRNAs	O
.	O

We	O
also	O
obtained	O
8	O
significantly	O
up	O
-	O
regulated	O
miRNAs	O
(	O
rno	O
-	O
miR	O
-	O
199a	O
-	O
5p	O
,	O
−	O
214	O
,	O
−	O
146b	O
,	O
−	O
21	O
,	O
−	O
34a	O
,	O
−	O
132	O
,	O
−	O
31	O
and	O
−	O
503	O
)	O
in	O
diseased	O
kidneys	O
of	O
PKD	B-DS
/	O
Mhm	O
rats	B-OG
.	O

Additionally	O
,	O
the	O
binding	O
site	O
overrepresentation	O
and	O
pathway	O
enrichment	O
analyses	O
were	O
accomplished	O
on	O
the	O
putative	O
targets	O
of	O
these	O
8	O
miRNAs	O
.	O

7	O
out	O
of	O
these	O
8	O
miRNAs	O
and	O
their	O
possible	O
interactions	O
have	O
not	O
been	O
previously	O
described	O
in	O
ADPKD	B-DS
.	O

We	O
have	O
shown	O
a	O
strong	O
overlap	O
of	O
functional	O
patterns	O
(	O
pathways	O
)	O
between	O
deregulated	O
miRNAs	O
and	O
mRNAs	O
in	O
the	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
rat	B-OG
model	O
.	O

Our	O
findings	O
suggest	O
that	O
several	O
miRNAs	O
may	O
be	O
associated	O
in	O
regulating	O
pathways	O
in	O
ADPKD	B-DS
.	O

We	O
further	O
describe	O
novel	O
miRNAs	O
and	O
their	O
possible	O
targets	O
in	O
ADPKD	B-DS
,	O
which	O
will	O
open	O
new	O
avenues	O
to	O
understand	O
the	O
pathogenesis	O
of	O
human	B-OG
ADPKD	B-DS
.	O

Furthermore	O
they	O
could	O
serve	O
as	O
a	O
useful	O
resource	O
for	O
anti	O
-	O
fibrotic	O
therapeutics	O
.	O

Introduction	O

MicroRNAs	O
(	O
miRNAs	O
)	O
comprise	O
a	O
recently	O
discovered	O
class	O
of	O
small	O
,	O
non	O
-	O
coding	O
RNA	O
molecules	O
of	O
21	O
–	O
25	O
nucleotides	O
in	O
length	O
that	O
regulate	O
the	O
gene	O
expression	O
by	O
base	O
-	O
pairing	O
with	O
the	O
transcripts	O
of	O
their	O
targets	O
i	O
.	O
e	O
.	O
protein	O
-	O
coding	O
genes	O
,	O
leading	O
to	O
down	O
-	O
regulation	O
or	O
repression	O
of	O
the	O
target	O
genes	O
[	O
1	O
].	O

However	O
,	O
target	O
gene	O
activation	O
has	O
also	O
been	O
described	O
[	O
2	O
].	O

miRNAs	O
are	O
involved	O
in	O
diverse	O
regulatory	O
pathways	O
,	O
including	O
control	O
of	O
developmental	O
timing	O
,	O
apoptosis	O
,	O
cell	O
proliferation	O
,	O
cell	O
differentiation	O
,	O
modulation	O
of	O
immune	O
response	O
to	O
macrophages	O
and	O
organ	O
development	O
[	O
1	O
],	O
[	O
3	O
]	O
and	O
are	O
associated	O
with	O
a	O
wide	O
range	O
of	O
human	B-OG
diseases	O
[	O
3	O
],	O
[	O
4	O
],	O
[	O
5	O
].	O

Cilia	O
,	O
hair	O
like	O
structures	O
[	O
6	O
],	O
are	O
evolutionary	O
conserved	O
organelles	O
that	O
extend	O
from	O
the	O
cell	O
surface	O
into	O
extracellular	O
space	O
[	O
7	O
]	O
to	O
perform	O
diverse	O
biological	O
functions	O
,	O
including	O
whole	O
-	O
cell	O
locomotion	O
,	O
fluid	O
movement	O
;	O
photo	O
-,	O
chemo	O
-,	O
and	O
mechanosensation	O
and	O
sexual	O
reproduction	O
.	O

Recent	O
findings	O
show	O
an	O
important	O
role	O
of	O
primary	O
cilia	O
in	O
several	O
signal	O
transduction	O
pathways	O
,	O
including	O
Wnt	B-GP
[	O
8	O
],	O
Hedgehog	B-GP
[	O
9	O
],	O
platelet	B-GP
-	I-GP
derived	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
-	I-GP
alpha	I-GP
(	O
PDGFRα	B-GP
)	O
[	O
10	O
]	O
signaling	O
cascades	O
and	O
cell	O
cycle	O
regulation	O
[	O
11	O
].	O

The	O
biological	O
importance	O
of	O
primary	O
cilia	O
in	O
human	B-OG
diseases	O
was	O
ignored	O
for	O
a	O
long	O
time	O
;	O
however	O
the	O
dysfunction	O
of	O
cilia	O
and	O
the	O
basal	O
body	O
has	O
recently	O
been	O
recognised	O
in	O
numerous	O
human	B-OG
pathologies	O
(	O
also	O
termed	O
as	O
“	O
ciliopathies	B-DS
”	O
or	O
“	O
cilia	B-DS
-	I-DS
related	I-DS
disorders	I-DS
”)	O
including	O
polycystic	B-DS
kidney	I-DS
diseases	I-DS
(	O
PKD	B-DS
),	O
nephronophthisis	B-DS
(	O
NPHP	B-DS
),	O
Bardet	B-DS
-	I-DS
Biedl	I-DS
syndrome	I-DS
(	O
BBS	B-DS
)	O
and	O
Oral	B-DS
-	I-DS
facial	I-DS
-	I-DS
digital	I-DS
syndrome	I-DS
(	O
OFD	B-DS
).	O

According	O
to	O
the	O
ciliary	O
hypothesis	O
most	O
of	O
the	O
proteins	O
of	O
cystic	B-DS
kidney	I-DS
diseases	I-DS
in	O
humans	B-OG
,	O
rats	B-OG
,	O
mice	B-OG
,	O
or	O
zebrafish	B-OG
are	O
expressed	O
in	O
primary	O
cilia	O
or	O
centrosomes	O
of	O
the	O
renal	O
epithelial	O
cells	O
[	O
7	O
].	O

Autosomal	B-DS
dominant	I-DS
polycystic	I-DS
kidney	I-DS
disease	I-DS
(	O
ADPKD	B-DS
)	O
is	O
a	O
frequent	O
monogenic	O
renal	B-DS
disease	I-DS
which	O
occurs	O
worldwide	O
with	O
a	O
prevalence	O
of	O
about	O
1	O
∶	O
1	O
,	O
000	O
[	O
12	O
].	O

This	O
is	O
characterised	O
by	O
development	O
of	O
fluid	O
filled	O
renal	O
,	O
hepatic	O
and	O
pancreatic	B-DS
cysts	I-DS
.	O

Nonetheless	O
,	O
the	O
epigenetic	O
factors	O
which	O
regulate	O
cystogenesis	O
are	O
still	O
unknown	O
.	O

Although	O
,	O
accumulating	O
evidence	O
suggests	O
several	O
potential	O
mechanisms	O
such	O
as	O
deregulated	O
cellular	O
proliferation	O
,	O
abnormal	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
),	O
secretion	O
of	O
fluids	O
into	O
the	O
tubular	O
lumen	O
,	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
),	O
irregular	O
extracellular	O
matrix	O
interaction	O
(	O
ECM	O
)	O
and	O
defective	O
planar	O
cell	O
polarity	O
(	O
PCP	O
)	O
could	O
promote	O
cyst	B-DS
formation	O
in	O
ADPKD	B-DS
[	O
13	O
],	O
[	O
14	O
],	O
[	O
15	O
].	O

For	O
example	O
,	O
a	O
primary	O
defect	O
in	O
apoptotic	O
regulation	O
(	O
e	O
.	O
g	O
.	O
bcl	B-GP
-	I-GP
2	I-GP
null	O
mice	B-OG
)	O
can	O
result	O
in	O
a	O
cystic	O
phenotype	O
[	O
16	O
].	O

Moreover	O
,	O
the	O
kidney	O
-	O
specific	O
overexpression	O
of	O
Myc	B-GP
leads	O
to	O
a	O
cystic	O
phenotype	O
and	O
an	O
increase	O
in	O
both	O
proliferation	O
and	O
apoptosis	O
[	O
17	O
],	O
[	O
18	O
].	O

In	O
another	O
study	O
,	O
the	O
cAMP	O
has	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
stimulating	O
cell	O
proliferation	O
and	O
fluid	O
secretion	O
associated	O
with	O
cyst	B-DS
formation	O
in	O
ADPKD	B-DS
[	O
13	O
].	O

Interestingly	O
,	O
the	O
knocking	O
out	O
of	O
aquaporins	B-GP
(	O
such	O
as	O
AQP11	B-GP
)	O
results	O
in	O
cysts	B-DS
formation	O
and	O
finally	O
leads	O
to	O
renal	B-DS
failure	I-DS
,	O
which	O
is	O
similar	O
to	O
PKD	B-DS
[	O
15	O
].	O

Aberrant	O
increases	O
in	O
basement	O
membrane	O
components	O
(	O
e	O
.	O
g	O
.,	O
Laminin	B-GP
,	O
Fibronectin	B-GP
and	O
Collagen	B-GP
IV	I-GP
)	O
have	O
also	O
been	O
described	O
to	O
cause	O
PKD	B-DS
.	O

Due	O
to	O
these	O
changes	O
,	O
the	O
basement	O
membrane	O
could	O
contribute	O
to	O
cyst	B-DS
initiation	O
and	O
expansion	O
[	O
19	O
],	O
[	O
20	O
].	O

Of	O
note	O
,	O
the	O
key	O
roles	O
of	O
metabolic	O
pathways	O
and	O
their	O
activators	O
have	O
also	O
been	O
reported	O
in	O
the	O
progression	O
of	O
chronic	B-DS
kidney	I-DS
diseases	I-DS
(	O
CKD	B-DS
)	O
in	O
human	B-OG
[	O
21	O
],	O
[	O
22	O
].	O

Mutant	O
studies	O
have	O
identified	O
some	O
players	O
in	O
PKD	B-DS
development	O
and	O
a	O
transcriptional	O
network	O
involving	O
Hepatocyte	B-GP
Nuclear	I-GP
Factor	I-GP
1β	I-GP
(	O
HNF1β	B-GP
)	O
[	O
23	O
],	O
HNF1α	B-GP
[	O
24	O
],	O
HNF4α	B-GP
and	O
GLIS2	B-GP
[	O
25	O
]	O
have	O
been	O
described	O
recently	O
.	O

Rats	B-OG
or	O
mice	B-OG
have	O
been	O
used	O
as	O
common	O
model	O
systems	O
for	O
the	O
study	O
of	O
PKD	B-DS
.	O

The	O
inbred	O
Hannover	O
rat	B-OG
,	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+),	O
has	O
been	O
efficiently	O
used	O
as	O
a	O
model	O
for	O
human	B-OG
PKD	B-DS
[	O
26	O
],	O
[	O
27	O
].	O

It	O
is	O
an	O
autosomal	O
dominant	O
model	O
for	O
PKD	B-DS
resulting	O
in	O
cyst	B-DS
formation	O
and	O
slowly	O
progressive	O
chronic	B-DS
renal	I-DS
failure	I-DS
[	O
26	O
],	O
[	O
27	O
].	O

In	O
the	O
current	O
investigation	O
,	O
(	O
1	O
)	O
we	O
performed	O
microarray	O
profiles	O
using	O
the	O
PKD	B-DS
/	O
Mhm	O
[	O
26	O
],	O
[	O
27	O
]	O
to	O
measure	O
the	O
transcriptional	O
changes	O
(	O
mRNA	O
and	O
miRNAs	O
expressions	O
),	O
(	O
2	O
)	O
comparative	O
transcriptomic	O
studies	O
were	O
conducted	O
to	O
elucidate	O
the	O
similarities	O
with	O
human	B-OG
ADPKD	B-DS
[	O
28	O
],	O
mouse	B-OG
(	O
PKD1L3	O
/	O
L3	O
[	O
29	O
]	O
and	O
PKD1	B-GP
−/−	O
[	O
30	O
]),	O
Hnf1α	B-GP
-	O
deficient	O
[	O
24	O
]	O
and	O
Glis2lacZ	O
/	O
lacZ	O
[	O
25	O
],	O
and	O
(	O
3	O
)	O
in	O
addition	O
we	O
investigated	O
the	O
possible	O
regulatory	O
roles	O
of	O
miRNAs	O
on	O
the	O
expression	O
levels	O
of	O
mRNAs	O
change	O
in	O
PKD	B-DS
/	O
Mhm	O
using	O
miRWalk	O
database	O
[	O
31	O
].	O

We	O
also	O
conducted	O
miRNA	O
binding	O
site	O
enrichment	O
analysis	O
to	O
identify	O
the	O
overrepresented	O
miRNAs	O
.	O

Furthermore	O
,	O
pathway	O
and	O
Gene	O
Ontology	O
analyses	O
were	O
performed	O
to	O
evaluate	O
enriched	O
functional	O
patterns	O
.	O

We	O
predicted	O
miRNAs	O
that	O
could	O
target	O
significant	O
pathways	O
in	O
ADPKD	B-DS
.	O
Figure	O
1	O
depicts	O
the	O
workflow	O
of	O
this	O
study	O
.	O

Our	O
results	O
suggest	O
that	O
several	O
miRNAs	O
may	O
be	O
involved	O
in	O
regulating	O
the	O
genetic	O
switches	O
in	O
PKD	B-DS
.	O

Additionally	O
,	O
we	O
describe	O
novel	O
possible	O
miRNA	O
:	O
mRNA	O
signatures	O
.	O

Systematic	O
workflow	O
to	O
explore	O
functional	O
regulatory	O
patterns	O
in	O
PKD	B-DS
.	O

Methods	O

Ethics	O
Statement	O

An	O
ethical	O
approval	O
was	O
granted	O
by	O
Regierungspraesidium	O
Nordbaden	O
to	O
conduct	O
this	O
experiment	O
on	O
animals	B-OG
.	O

Animal	B-OG
Model	O

After	O
approximately	O
40	O
generations	O
of	O
breeding	O
Han	O
:	O
SPRD	O
-	O
cy	O
rats	B-OG
which	O
carry	O
a	O
dominant	O
mutation	O
that	O
causes	O
cystic	B-DS
kidneys	I-DS
and	O
is	O
an	O
accepted	O
model	O
for	O
human	B-OG
PKD	B-DS
,	O
was	O
registered	O
as	O
PKD	B-DS
/	O
Mhm	O
-	O
cy	O
inbred	O
strain	O
of	O
rats	B-OG
:	O
polycystic	B-DS
kidney	I-DS
diseases	I-DS
,	O
Mannheim	O
,	O
Germany	O
hereafter	O
designated	O
as	O
PKD	B-DS
/	O
Mhm	O
.	O

In	O
this	O
study	O
,	O
PKD	B-DS
/	O
Mhm	O
heterozygous	O
(	O
cy	O
/+)	O
and	O
homozygous	O
unaffected	O
(+/+)	O
36	O
days	O
old	O
animals	B-OG
,	O
littermates	O
were	O
investigated	O
to	O
profile	O
expression	O
differences	O
in	O
mRNAs	O
and	O
miRNAs	O
.	O

Heterozygous	O
rats	B-OG
develop	O
slowly	O
progressive	O
cystic	B-DS
disease	I-DS
with	O
interstitial	B-DS
fibrosis	I-DS
and	O
thickened	O
basement	O
membranes	O
[	O
32	O
].	O

About	O
75	O
%	O
of	O
the	O
cysts	B-DS
are	O
derived	O
from	O
the	O
proximal	O
tubule	O
.	O

The	O
cystic	O
transformation	O
starts	O
with	O
a	O
sharp	O
onset	O
of	O
basement	O
membrane	O
alterations	O
and	O
a	O
loss	O
of	O
epithelial	O
differentiation	O
restricted	O
to	O
small	O
focal	O
areas	O
[	O
26	O
].	O

There	O
is	O
a	O
substantial	O
matrix	O
overproduction	O
and	O
accumulation	O
of	O
collagen	B-GP
IV	I-GP
and	O
laminin	B-GP
[	O
26	O
],	O
[	O
33	O
].	O

The	O
control	O
and	O
diseased	O
animals	B-OG
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
.	O

The	O
left	O
and	O
right	O
kidneys	O
were	O
immediately	O
removed	O
and	O
preserved	O
for	O
histological	O
analyses	O
[	O
34	O
],	O
and	O
the	O
genotypes	O
were	O
confirmed	O
.	O

RNA	O
Isolation	O
and	O
Affymetrix	O
mRNA	O
Microarray	O

Total	O
RNA	O
was	O
extracted	O
using	O
TRIzol	O
method	O
according	O
to	O
manufacturer	O
’	O
s	O
protocol	O
(	O
Invitrogen	O
Life	O
Technologies	O
).	O

cDNA	O
synthesis	O
was	O
performed	O
using	O
the	O
SuperScript	O
Choice	O
System	O
(	O
Invitrogen	O
Life	O
Technologies	O
,	O
Invitrogen	O
Corporation	O
)	O
according	O
to	O
manufacturer	O
’	O
s	O
protocol	O
.	O

Biotin	O
-	O
labeled	O
cRNA	O
was	O
produced	O
using	O
ENZO	O
BioArray	O
HighYield	O
RNA	O
Transcript	O
Labeling	O
Kit	O
.	O

Standard	O
protocol	O
from	O
Affymetrix	O
(	O
Santa	O
Clara	O
,	O
CA	O
)	O
with	O
3	O
.	O
3	O
µL	O
of	O
cDNA	O
was	O
used	O
for	O
the	O
in	O
vitro	O
transcription	O
(	O
IVT	O
).	O

Clean	O
-	O
up	O
of	O
the	O
IVT	O
product	O
was	O
done	O
using	O
CHROMA	O
SPIN	O
-	O
100	O
columns	O
(	O
Clontech	O
,	O
USA	O
).	O

Spectrophotometric	O
analysis	O
was	O
used	O
for	O
quantification	O
of	O
cRNA	O
with	O
acceptable	O
A260	O
/	O
A280	O
ratio	O
of	O
1	O
.	O
9	O
to	O
2	O
.	O
1	O
.	O

After	O
that	O
the	O
cRNA	O
was	O
fragmented	O
using	O
Affymetrix	O
defined	O
protocol	O
.	O

Labeled	O
and	O
fragmented	O
cRNA	O
was	O
hybridised	O
to	O
10	O
Affymetrix	O
Rat	B-OG
230_2	O
microarrays	O
for	O
16	O
hours	O
at	O
45	O
°	O
C	O
using	O
Affymetrix	O
defined	O
protocol	O
.	O

Microarrays	O
were	O
washed	O
using	O
an	O
Affymetrix	O
fluidics	O
station	O
450	O
and	O
stained	O
initially	O
with	O
streptavidin	B-GP
phycoerythrin	B-GP
(	O
SA	B-GP
-	O
PE	B-GP
).	O

For	O
each	O
sample	O
the	O
signal	O
was	O
further	O
enhanced	O
by	O
incubation	O
with	O
biotinylated	O
goat	B-OG
anti	O
-	O
streptavidin	B-GP
followed	O
by	O
a	O
second	O
incubation	O
with	O
SA	B-GP
-	O
PE	B-GP
and	O
a	O
second	O
round	O
of	O
intensities	O
were	O
measured	O
.	O

Microarrays	O
were	O
scanned	O
with	O
Affymetrix	O
Genechip	O
scanner	O
3000	O
controlled	O
by	O
Affymetrix	O
Genechip	O
Command	O
Console	O
(	O
Affymetrix	O
Microarray	O
Suite	O
)	O
software	O
.	O

RNA	O
Isolation	O
and	O
Affymetrix	O
miRNA	O
Microarray	O

Total	O
RNA	O
was	O
isolated	O
using	O
Trizol	O
method	O
as	O
described	O
for	O
mRNA	O
microarrays	O
followed	O
by	O
additional	O
purification	O
using	O
the	O
miRNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
).	O

RNA	O
was	O
tested	O
by	O
capillary	O
electrophoresis	O
on	O
an	O
Agilent	O
2100	O
bioanalyzer	O
(	O
Agilent	O
)	O
and	O
high	O
quality	O
was	O
confirmed	O
.	O

1	O
µg	O
of	O
total	O
RNA	O
was	O
Biotinylated	O
using	O
FlashTag	O
Biotin	O
RNA	O
Labeling	O
Kit	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
(	O
Genisphere	O
LLC	O
).	O

Labeled	O
product	O
was	O
hybridised	O
to	O
4	O
Affymetrix	O
miRNA	O
microarrays	O
(	O
Version	O
1	O
.	O
0	O
)	O
for	O
16	O
hours	O
at	O
48	O
°	O
C	O
with	O
60	O
rpm	O
by	O
using	O
a	O
GeneChip	O
Hybridisation	O
oven	O
640	O
.	O

Microarrays	O
were	O
then	O
washed	O
and	O
stained	O
.	O

Thereafter	O
,	O
microarrays	O
were	O
scanned	O
.	O

Statistical	O
Analysis	O
of	O
Microarray	O
Data	O

Before	O
statistical	O
evaluation	O
,	O
quality	O
control	O
and	O
scatter	O
plot	O
analyses	O
were	O
carried	O
out	O
to	O
minimise	O
bad	O
quality	O
intensity	O
signals	O
,	O
variation	O
during	O
chip	O
hybridisation	O
and	O
separation	O
of	O
groups	O
used	O
for	O
genetic	O
profiling	O
(	O
Text	O
S1	O
).	O

Thereafter	O
,	O
the	O
raw	O
fluorescence	O
intensity	O
values	O
were	O
normalised	O
by	O
applying	O
quantile	O
normalisation	O
.	O

Differential	O
mRNA	O
expression	O
was	O
analysed	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
[	O
35	O
],	O
using	O
SAS	O
JMP7	O
Genomics	O
,	O
version	O
4	O
,	O
from	O
SAS	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
).	O

A	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
correction	O
was	O
taken	O
for	O
multiple	O
testing	O
with	O
5	O
%	O
level	O
of	O
significance	O
(	O
α	O
=	O
0	O
.	O
05	O
).	O

A	O
custom	O
chip	O
definition	O
file	O
(	O
CDF	O
,	O
version	O
14	O
with	O
Entrez	O
GeneIDs	O
based	O
gene	O
definitions	O
)	O
was	O
employed	O
to	O
annotate	O
the	O
arrays	O
[	O
36	O
].	O

Similarly	O
,	O
the	O
miRNA	O
microarrays	O
were	O
analysed	O
using	O
customised	O
“	O
R	O
script	O
”	O
(	O
Bioconductor	O
version	O
2	O
.	O
10	O
including	O
affy	O
and	O
limma	O
packages	O
)	O
to	O
obtain	O
differentially	O
regulated	O
miRNAs	O
.	O

To	O
verify	O
the	O
results	O
of	O
miRNA	O
microarray	O
,	O
qRT	O
-	O
PCR	O
assays	O
(	O
TaqMan	O
miRNA	O
assays	O
)	O
were	O
performed	O
.	O

Reverse	O
Transcription	O
and	O
Quantitative	O
Real	O
-	O
time	O
PCR	O
(	O
qPCR	O
)	O
Analysis	O
of	O
miRNAs	O

The	O
reverse	B-GP
transcriptase	I-GP
reactions	O
were	O
performed	O
according	O
to	O
“	O
TaqMan	O
MicroRNA	O
Assays	O
”	O
protocol	O
(	O
Applied	O
Biosystems	O
,	O
USA	O
).	O

TaqMan	O
MicroRNA	O
Reverse	O
Transcription	O
kit	O
(	O
Applied	O
Biosystems	O
)	O
was	O
used	O
for	O
cDNA	O
synthesis	O
.	O

The	O
Reverse	O
Transcription	O
(	O
RT	O
)	O
mix	O
was	O
prepared	O
for	O
cDNA	O
synthesis	O
and	O
transferred	O
into	O
a	O
single	O
reaction	O
tube	O
.	O

2	O
.	O
5	O
µL	O
diluted	O
RNA	O
(	O
10	O
ng	O
)	O
was	O
added	O
to	O
each	O
tube	O
.	O

The	O
RT	O
reaction	O
was	O
accomplished	O
in	O
the	O
cycler	O
with	O
different	O
incubations	O
as	O
indicated	O
in	O
the	O
“	O
TaqMan	O
MicroRNA	O
Assays	O
”	O
protocol	O
(	O
Applied	O
Biosystems	O
,	O
USA	O
).	O

Then	O
Real	O
-	O
Time	O
PCR	O
was	O
performed	O
.	O

Thereafter	O
,	O
a	O
master	O
mix	O
was	O
prepared	O
by	O
adding	O
5	O
µL	O
universal	O
PCR	O
Master	O
Mix	O
with	O
NO	O
UNGase	O
from	O
Applied	O
Biosystems	O
and	O
1	O
µL	O
TaqMan	O
probe	O
.	O

The	O
prepared	O
master	O
mix	O
was	O
aliquotted	O
on	O
the	O
96	O
-	O
well	O
plate	O
and	O
then	O
4	O
µL	O
of	O
the	O
template	O
(	O
cDNA	O
)	O
was	O
added	O
.	O

Cycling	O
conditions	O
were	O
kept	O
as	O
indicated	O
.	O

The	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
on	O
MxPro	O
–	O
Mx3005P	O
v4	O
.	O
01	O
Build	O
369	O
,	O
Schema	O
80	O
quantitative	O
PCR	O
software	O
from	O
Stratagene	O
.	O

All	O
the	O
reactions	O
were	O
run	O
in	O
triplicates	O
.	O

The	O
threshold	O
cycle	O
(	O
CT	O
)	O
is	O
defined	O
as	O
the	O
fractional	O
cycle	O
number	O
at	O
which	O
the	O
fluorescence	O
passes	O
the	O
fixed	O
threshold	O
.	O

The	O
expression	O
of	O
miRNA	O
genes	O
between	O
control	O
and	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
animals	B-OG
was	O
determined	O
according	O
to	O
manufacturer	O
’	O
s	O
protocol	O
.	O

The	O
mir	O
-	O
193a	O
was	O
chosen	O
as	O
an	O
endogenous	O
control	O
because	O
of	O
its	O
uniform	O
expression	O
in	O
PKD	B-DS
/	O
Mhm	O
[	O
34	O
].	O

The	O
fold	O
change	O
expression	O
of	O
miRNAs	O
among	O
the	O
two	O
groups	O
was	O
examined	O
by	O
MxPro	O
–	O
Mx3005P	O
software	O
.	O

The	O
significance	O
of	O
differences	O
in	O
relative	O
expression	O
of	O
miRNAs	O
among	O
the	O
two	O
groups	O
was	O
tested	O
by	O
implementing	O
t	O
-	O
test	O
method	O
in	O
‘	O
R	O
’.	O

The	O
relative	O
expression	O
plots	O
of	O
miRNAs	O
were	O
created	O
by	O
using	O
the	O
same	O
“	O
R	O
script	O
”.	O

Gene	O
Ontology	O
and	O
Pathway	O
Enrichment	O
Analysis	O

The	O
DAVID	O
database	O
[	O
37	O
]	O
was	O
utilised	O
to	O
collect	O
the	O
statistically	O
enriched	O
pathways	O
and	O
GO	O
terms	O
information	O
for	O
1	O
,	O
573	O
up	O
-	O
and	O
1	O
,	O
760	O
down	O
-	O
regulated	O
genes	O
that	O
may	O
modulate	O
cystogenesis	O
.	O

Comparison	O
with	O
Other	O
ADPKD	B-DS
Datasets	O

ADPKD	B-DS
datasets	O
with	O
mutation	O
in	O
PKD1	B-GP
:	O
Pkd1L3	O
/	O
L3	O
[	O
29	O
],	O
human	B-OG
ADPKD	B-DS
[	O
28	O
],	O
Pkd1	B-GP
−/−	O
[	O
30	O
]	O
and	O
Pandey	O
et	O
al	O
[	O
34	O
]	O
were	O
downloaded	O
from	O
4	O
published	O
studies	O
.	O

In	O
human	B-OG
ADPKD	B-DS
study	O
,	O
the	O
samples	O
were	O
collected	O
from	O
5	O
polycystic	B-DS
kidneys	I-DS
having	O
renal	B-DS
cysts	I-DS
of	O
different	O
sizes	O
:	O
small	O
,	O
medium	O
and	O
large	O
.	O

The	O
size	O
of	O
each	O
cyst	B-DS
was	O
determined	O
by	O
measuring	O
the	O
amount	O
of	O
cystic	O
fluid	O
.	O

The	O
volume	O
cut	O
-	O
off	O
values	O
of	O
cystic	O
fluid	O
for	O
defining	O
the	O
different	O
sizes	O
were	O
set	O
to	O
less	O
than	O
1	O
ml	O
,	O
between	O
10	O
to	O
25	O
ml	O
,	O
and	O
greater	O
than	O
50	O
ml	O
for	O
small	O
,	O
medium	O
and	O
large	O
cysts	B-DS
,	O
respectively	O
.	O

All	O
the	O
patients	O
used	O
in	O
this	O
study	O
were	O
shown	O
to	O
have	O
PKD1	B-GP
by	O
DNA	O
linkage	O
or	O
documentation	O
of	O
pathogenic	O
mutation	O
[	O
28	O
].	O

The	O
lists	O
of	O
significantly	O
regulated	O
genes	O
of	O
these	O
4	O
studies	O
were	O
compared	O
with	O
the	O
differentially	O
expressed	O
genes	O
observed	O
in	O
the	O
cystic	B-DS
kidneys	I-DS
of	O
PKD	B-DS
/	O
Mhm	O
rats	B-OG
.	O

Moreover	O
,	O
the	O
significantly	O
regulated	O
genes	O
in	O
cystic	B-DS
kidneys	I-DS
of	O
PKD	B-DS
/	O
Mhm	O
rats	B-OG
were	O
also	O
compared	O
with	O
two	O
other	O
studies	O
that	O
were	O
conducted	O
on	O
Hnf1α	B-GP
-	O
deficient	O
mice	B-OG
[	O
24	O
]	O
and	O
Glis2lacZ	O
/	O
lacZ	O
model	O
[	O
25	O
].	O

miRNA	O
Target	O
Predictions	O
and	O
Enrichment	O
Analysis	O

An	O
“	O
in	O
-	O
silico	O
”	O
screening	O
of	O
miRNA	O
binding	O
site	O
predictions	O
was	O
carried	O
out	O
within	O
deregulated	O
genes	O
by	O
adopting	O
the	O
miRWalk	O
algorithm	O
[	O
31	O
].	O

Furthermore	O
,	O
a	O
meta	O
-	O
analysis	O
for	O
miRNA	O
binding	O
site	O
predictions	O
was	O
performed	O
using	O
the	O
comprehensive	O
platform	O
of	O
miRWalk	O
database	O
.	O

The	O
comparative	O
platform	O
of	O
miRWalk	O
database	O
supplies	O
the	O
possible	O
miRNA	O
binding	O
sites	O
resulting	O
from	O
10	O
different	O
prediction	O
datasets	O
.	O

Moreover	O
,	O
integrating	O
the	O
results	O
from	O
multiple	O
miRNA	O
-	O
target	O
prediction	O
algorithms	O
can	O
be	O
very	O
helpful	O
in	O
reducing	O
the	O
false	O
positive	O
targets	O
[	O
38	O
],	O
[	O
39	O
].	O

Thus	O
,	O
the	O
putative	O
targets	O
(	O
genes	O
)	O
information	O
for	O
deregulated	O
miRNAs	O
were	O
downloaded	O
by	O
interrogating	O
the	O
“	O
MicroRNA	O
Target	O
web	O
interface	O
”	O
which	O
is	O
implemented	O
under	O
the	O
“	O
Predicted	O
Target	O
module	O
”	O
of	O
miRWalk	O
database	O
and	O
then	O
the	O
commonly	O
predicted	O
genes	O
were	O
separated	O
.	O

For	O
overrepresentation	O
analysis	O
of	O
miRNA	O
binding	O
site	O
,	O
a	O
customised	O
“	O
R	O
script	O
”	O
was	O
used	O
by	O
implementing	O
Fishers	O
’	O
exact	O
test	O
with	O
Benjamini	O
and	O
Hochberg	O
(	O
BH	O
)	O
as	O
multiple	O
testing	O
(	O
background	O
correction	O
)	O
with	O
5	O
%	O
level	O
of	O
significance	O
.	O

Results	O

Statistical	O
Analysis	O
of	O
mRNA	O
Microarray	O
Profiling	O
in	O
PKD	B-DS

The	O
expression	O
of	O
3	O
,	O
333	O
genes	O
was	O
significantly	O
changed	O
between	O
diseased	O
and	O
healthy	O
kidneys	O
(	O
Table	O
S1	O
).	O

We	O
found	O
1	O
,	O
573	O
genes	O
as	O
significantly	O
up	O
-	O
regulated	O
,	O
whereas	O
the	O
remaining	O
1	O
,	O
760	O
genes	O
were	O
significantly	O
down	O
-	O
regulated	O
in	O
diseased	O
kidneys	O
compared	O
to	O
healthy	O
.	O

Several	O
markers	O
for	O
the	O
severity	O
of	O
tubular	O
damage	O
such	O
as	O
Havcr1	B-GP
and	O
Clu	B-GP
were	O
found	O
highly	O
expressed	O
in	O
PKD	B-DS
.	O

These	O
genes	O
are	O
involved	O
in	O
tissue	O
remodelling	O
,	O
immune	O
/	O
inflammatory	O
response	O
,	O
cell	O
adhesion	O
,	O
cell	O
proliferation	O
,	O
cell	O
migration	O
and	O
metabolic	O
pathways	O
[	O
37	O
].	O
Figure	O
2	O
shows	O
the	O
top	O
30	O
significantly	O
regulated	O
(	O
15	O
up	O
-	O
and	O
15	O
down	O
-	O
regulated	O
)	O
genes	O
,	O
according	O
to	O
their	O
p	O
-	O
values	O
.	O

Differential	O
expression	O
of	O
top	O
30	O
genes	O
in	O
PKD	B-DS
and	O
control	O
animals	B-OG
.	O

The	O
heatmap	O
was	O
produced	O
by	O
clustering	O
the	O
data	O
matrix	O
of	O
top	O
30	O
genes	O
using	O
Pearson	O
correlation	O
.	O

The	O
gene	O
clustering	O
tree	O
is	O
shown	O
on	O
the	O
left	O
and	O
the	O
sample	O
clustering	O
tree	O
is	O
shown	O
on	O
the	O
top	O
.	O

The	O
other	O
information	O
such	O
as	O
fold	O
change	O
expression	O
,	O
p	O
-	O
value	O
,	O
gene	O
symbol	O
and	O
involvement	O
are	O
given	O
on	O
the	O
right	O
.	O

The	O
samples	O
are	O
broadly	O
divided	O
into	O
two	O
groups	O
,	O
healthy	O
(	O
control	O
)	O
and	O
PKD	B-DS
.	O

The	O
color	O
scale	O
shown	O
at	O
the	O
top	O
illustrates	O
the	O
relative	O
expression	O
level	O
of	O
the	O
indicated	O
genes	O
across	O
all	O
samples	O
.	O

We	O
also	O
observed	O
up	O
-	O
regulation	O
of	O
multiple	O
developmental	O
genes	O
including	O
secreted	O
modulators	O
(	O
Bmp1	B-GP
,	O
Mmp12	B-GP
and	O
Kcnj8	B-GP
)	O
and	O
integrin	B-GP
receptors	I-GP
subunit	O
(	O
Itga1	B-GP
,	O
5	O
and	O
11	O
)	O
in	O
PKD	B-DS
.	O

Microarray	O
analysis	O
also	O
showed	O
many	O
differentially	O
expressed	O
transcription	B-GP
factors	I-GP
(	O
TFs	B-GP
)	O
such	O
as	O
Myc	B-GP
,	O
Jun	B-GP
,	O
Stat3	B-GP
and	O
Smad1	B-GP
were	O
up	O
-	O
regulated	O
,	O
whereas	O
Sip1	B-GP
,	O
Hnf1α	B-GP
,	O
Hnf4α	B-GP
and	O
Glis2	B-GP
were	O
down	O
-	O
regulated	O
in	O
diseased	O
kidneys	O
.	O

Functional	O
Enrichment	O
Analysis	O
of	O
Differentially	O
Regulated	O
Genes	O
in	O
PKD	B-DS

We	O
obtained	O
12	O
and	O
5	O
significantly	O
enriched	O
pathways	O
linked	O
with	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
,	O
respectively	O
(	O
Table	O
1	O
).	O

The	O
most	O
relevant	O
pathways	O
(	O
such	O
as	O
focal	O
adhesion	O
,	O
cell	O
cycle	O
,	O
ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O
,	O
regulation	O
of	O
actin	B-GP
cytoskeleton	O
and	O
MAPK	B-GP
signaling	O
)	O
were	O
found	O
significantly	O
up	O
-	O
regulated	O
in	O
PKD	B-DS
.	O

We	O
also	O
noted	O
5	O
significant	O
metabolic	O
pathways	O
on	O
down	O
-	O
regulated	O
genes	O
.	O

Moreover	O
,	O
45	O
and	O
2	O
GO	O
biological	O
processes	O
were	O
observed	O
to	O
be	O
associated	O
with	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
,	O
respectively	O
(	O
Table	O
2	O
).	O

Differentially	O
regulated	O
pathways	O
on	O
significantly	O
up	O
-	O
and	O
–	O
down	O
-	O
regulated	O
genes	O
.	O

Pathway	O

p	O
-	O
value	O

Fold	O
Enrichment	O

Benjamini	O
correction	O

Pathways	O
associated	O
with	O
significantly	O
up	O
-	O
regulated	O
genes	O

Focal	O
adhesion	O

1	O
.	O
47E	O
−	O
10	O

2	O
.	O
71	O

2	O
.	O
41E	O
−	O
08	O

Cell	O
cycle	O

6	O
.	O
32E	O
−	O
10	O

3	O
.	O
15	O

5	O
.	O
18E	O
−	O
08	O

ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O

3	O
.	O
79E	O
−	O
09	O

3	O
.	O
68	O

2	O
.	O
07E	O
−	O
07	O

DNA	O
replication	O

3	O
.	O
12E	O
−	O
05	O

4	O
.	O
10	O

0	O
.	O
001	O

Regulation	O
of	O
actin	B-GP
cytoskeleton	O

2	O
.	O
12E	O
−	O
04	O

1	O
.	O
90	O

0	O
.	O
004	O

Fc	B-GP
gamma	I-GP
R	I-GP
-	O
mediated	O
phagocytosis	O

2	O
.	O
48E	O
−	O
04	O

2	O
.	O
51	O

0	O
.	O
004	O

Pathways	O
in	O
cancer	O

3	O
.	O
77E	O
−	O
04	O

1	O
.	O
67	O

0	O
.	O
005	O

Hematopoietic	O
cell	O
lineage	O

4	O
.	O
63E	O
−	O
04	O

2	O
.	O
54	O

0	O
.	O
005	O

Chemokine	B-GP
signaling	O
pathway	O

5	O
.	O
93E	O
−	O
04	O

1	O
.	O
93	O

0	O
.	O
006	O

Leukocyte	O
transendothelial	O
migration	O

0	O
.	O
003	O

2	O
.	O
01	O

0	O
.	O
032	O

Neurotrophin	O
signaling	O
pathway	O

0	O
.	O
004	O

1	O
.	O
92	O

0	O
.	O
04	O

MAPK	B-GP
signaling	O
pathway	O

0	O
.	O
004	O

1	O
.	O
57	O

0	O
.	O
04	O

Pathways	O
associated	O
with	O
significantly	O
down	O
-	O
regulated	O
genes	O

Valine	O
,	O
leucine	O
and	O
isoleucine	O
degradation	O

1	O
.	O
19E	O
−	O
13	O

5	O
.	O
831178	O

2	O
.	O
17E	O
−	O
11	O

Fatty	O
acid	O
metabolism	O

4	O
.	O
22E	O
−	O
07	O

4	O
.	O
342839	O

3	O
.	O
84E	O
−	O
05	O

Citrate	O
cycle	O
(	O
TCA	O
cycle	O
)	O

6	O
.	O
70E	O
−	O
06	O

4	O
.	O
649392	O

4	O
.	O
06E	O
−	O
04	O

Pantothenate	O
and	O
CoA	O
biosynthesis	O

1	O
.	O
00E	O
−	O
04	O

5	O
.	O
722329	O

0	O
.	O
006	O

Propanoate	O
metabolism	O

5	O
.	O
00E	O
−	O
04	O

3	O
.	O
576456	O

0	O
.	O
01	O

Differentially	O
regulated	O
GO	O
biological	O
processes	O
associated	O
with	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
.	O

Gene	O
Ontology	O
Biological	O
Process	O

p	O
-	O
value	O

Fold	O
Enrichment	O

Benjamini	O
correction	O

GO	O
biological	O
processes	O
associated	O
with	O
up	O
-	O
regulated	O
genes	O

Regulation	O
of	O
cell	O
proliferation	O

1	O
.	O
76E	O
−	O
09	O

1	O
.	O
82	O

3	O
.	O
34E	O
−	O
07	O

Positive	O
regulation	O
of	O
developmental	O
process	O

3	O
.	O
42E	O
−	O
06	O

1	O
.	O
96	O

2	O
.	O
28E	O
−	O
04	O

Negative	O
regulation	O
of	O
signal	O
transduction	O

4	O
.	O
68E	O
−	O
06	O

2	O
.	O
23	O

2	O
.	O
92E	O
−	O
04	O

Response	O
to	O
oxygen	O
levels	O

1	O
.	O
67E	O
−	O
05	O

2	O
.	O
14	O

7	O
.	O
62E	O
−	O
04	O

Response	O
to	O
cytokine	B-GP
stimulus	O

1	O
.	O
82E	O
−	O
05	O

2	O
.	O
62	O

8	O
.	O
03E	O
−	O
04	O

Negative	O
regulation	O
of	O
cell	O
communication	O

2	O
.	O
20E	O
−	O
05	O

2	O
.	O
04	O

9	O
.	O
19E	O
−	O
04	O

Regulation	O
of	O
cell	O
cycle	O

5	O
.	O
13E	O
−	O
05	O

1	O
.	O
95	O

0	O
.	O
001	O

Aging	O

5	O
.	O
55E	O
−	O
05	O

2	O
.	O
27	O

0	O
.	O
001	O

Tissue	O
remodeling	O

6	O
.	O
42E	O
−	O
05	O

3	O
.	O
12	O

0	O
.	O
001	O

Actin	B-GP
filament	O
bundle	O
formation	O

8	O
.	O
51E	O
−	O
05	O

5	O
.	O
57	O

0	O
.	O
002	O

Response	O
to	O
mechanical	O
stimulus	O

2	O
.	O
01E	O
−	O
04	O

2	O
.	O
74	O

0	O
.	O
004	O

Intracellular	O
signaling	O
cascade	O

2	O
.	O
17E	O
−	O
04	O

1	O
.	O
39	O

0	O
.	O
005	O

Response	O
to	O
hypoxia	O

3	O
.	O
33E	O
−	O
04	O

1	O
.	O
97	O

0	O
.	O
007	O

Cytokine	B-GP
-	O
mediated	O
signaling	O

7	O
.	O
91E	O
−	O
04	O

2	O
.	O
75	O

0	O
.	O
014	O

Transforming	O
growth	O
factor	O
beta	O
receptor	O
signaling	O

0	O
.	O
001	O

3	O
.	O
06	O

0	O
.	O
021	O

Negative	O
regulation	O
of	O
cell	O
adhesion	O

0	O
.	O
001	O

3	O
.	O
56	O

0	O
.	O
022	O

Myeloid	O
leukocyte	O
activation	O

0	O
.	O
001	O

2	O
.	O
88	O

0	O
.	O
022	O

Transmembrane	O
receptor	O
protein	O
serine	O
/	O
threonine	O
kinase	O

0	O
.	O
001	O

2	O
.	O
40	O

0	O
.	O
023	O

Wnt	B-GP
receptor	O
signaling	O

0	O
.	O
001	O

2	O
.	O
38	O

0	O
.	O
026	O

Microtubule	O
-	O
based	O
process	O

0	O
.	O
002	O

1	O
.	O
80	O

0	O
.	O
031	O

Microtubule	O
cytoskeleton	O
organization	O

0	O
.	O
002	O

2	O
.	O
19	O

0	O
.	O
033	O

GO	O
biological	O
processes	O
associated	O
with	O
down	O
-	O
regulated	O
genes	O

Oxidation	O
reduction	O

4	O
.	O
26E	O
−	O
07	O

1	O
.	O
70	O

1	O
.	O
74E	O
−	O
04	O

Vesicle	O
-	O
mediated	O
transport	O

1	O
.	O
33E	O
−	O
05	O

1	O
.	O
72	O

0	O
.	O
002	O

Comparison	O
with	O
Other	O
ADPKD	B-DS
Data	O
Sets	O

We	O
attempted	O
to	O
derive	O
correlations	O
among	O
the	O
gene	O
expression	O
changes	O
in	O
PKD	B-DS
and	O
a	O
set	O
of	O
genes	O
that	O
modulate	O
disease	O
severity	O
in	O
our	O
rat	B-OG
model	O
,	O
and	O
human	B-OG
ADPKD	B-DS
.	O

We	O
compared	O
the	O
significantly	O
regulated	O
genes	O
of	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
rat	B-OG
models	O
with	O
data	O
obtained	O
from	O
3	O
other	O
published	O
studies	O
which	O
include	O
,	O
PKD1L3	O
/	O
L3	O
[	O
29	O
],	O
PKD1	B-GP
−/−	O
[	O
30	O
]	O
and	O
human	B-OG
ADPKD	B-DS
[	O
28	O
].	O

A	O
total	O
of	O
599	O
(	O
346	O
and	O
253	O
up	O
-,	O
and	O
down	O
-	O
regulated	O
,	O
respectively	O
)	O
dysregulated	O
genes	O
were	O
common	O
between	O
the	O
PKD1L3	O
/	O
L3	O
and	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
with	O
similar	O
expression	O
patterns	O
(	O
Table	O
S2	O
).	O

The	O
comparison	O
between	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
dataset	O
and	O
PKD1	B-GP
−/−	O
data	O
showed	O
37	O
common	O
genes	O
(	O
with	O
up	O
-	O
regulated	O
expression	O
)	O
(	O
Table	O
S3	O
).	O

In	O
a	O
comparison	O
of	O
our	O
data	O
with	O
human	B-OG
ADPKD	B-DS
dataset	O
,	O
a	O
total	O
of	O
38	O
dysregulated	O
genes	O
with	O
up	O
-	O
regulated	O
expression	O
patterns	O
were	O
observed	O
(	O
Table	O
S4	O
).	O

Moreover	O
,	O
we	O
obtained	O
315	O
up	O
-	O
and	O
127	O
down	O
-	O
regulated	O
genes	O
(	O
with	O
similar	O
expressions	O
)	O
when	O
our	O
PKD	B-DS
/	O
Mhm	O
dataset	O
was	O
compared	O
with	O
the	O
data	O
obtained	O
from	O
Pandey	O
et	O
al	O
[	O
34	O
]	O
(	O
Table	O
S5	O
).	O

Notably	O
,	O
many	O
pathways	O
(	O
such	O
as	O
focal	O
adhesion	O
,	O
cell	O
cycle	O
,	O
ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O
,	O
regulation	O
of	O
acting	O
cytoskeleton	O
,	O
Mapk	B-GP
and	O
metabolic	O
pathways	O
)	O
were	O
also	O
found	O
as	O
commonly	O
deregulated	O
in	O
both	O
datasets	O
.	O

miRNA	O
Microarray	O
Data	O
Analysis	O
in	O
PKD	B-DS
and	O
Validation	O
of	O
the	O
Findings	O

The	O
seven	O
miRNAs	O
i	O
.	O
e	O
.	O
rno	O
-	O
miR	O
-	O
146b	O
,	O
-	O
132	O
,	O
-	O
21	O
,	O
-	O
503	O
,	O
-	O
199a	O
-	O
5p	O
,	O
-	O
214	O
and	O
-	O
34a	O
were	O
determined	O
as	O
significantly	O
up	O
-	O
regulated	O
in	O
PKD	B-DS
as	O
depicted	O
in	O
Figure	O
3	O
.	O

Overview	O
of	O
fold	O
changes	O
of	O
miRNAs	O
versus	O
a	O
measure	O
of	O
statistical	O
significance	O
.	O

The	O
volcano	O
plot	O
shows	O
the	O
-	O
log10	O
(	O
p	O
-	O
value	O
)	O
on	O
the	O
y	O
-	O
axis	O
and	O
the	O
fold	O
change	O
(	O
log2	O
)	O
on	O
the	O
x	O
-	O
axis	O
.	O

A	O
cut	O
-	O
off	O
[-	O
log10	O
(	O
p	O
-	O
value	O
)	O
=	O
1	O
.	O
86	O
]	O
was	O
considered	O
to	O
determine	O
differentially	O
expressed	O
miRNAs	O
between	O
diseased	O
and	O
health	O
(	O
control	O
)	O
animals	B-OG
.	O

Seven	O
miRNAs	O
i	O
.	O
e	O
.	O
rno	O
-	O
miR	O
-	O
146b	O
,	O
-	O
132	O
,	O
-	O
21	O
,	O
-	O
503	O
,	O
-	O
199a	O
-	O
5p	O
,	O
-	O
214	O
and	O
-	O
34a	O
were	O
found	O
to	O
be	O
significantly	O
up	O
-	O
regulated	O
in	O
diseased	O
animals	B-OG
with	O
a	O
fold	O
change	O
≥	O
0	O
.	O
5	O
with	O
significant	O
p	O
-	O
value	O
≤	O
0	O
.	O
01	O
.	O

In	O
order	O
to	O
further	O
verify	O
the	O
results	O
of	O
miRNA	O
microarray	O
analysis	O
,	O
we	O
selected	O
three	O
candidates	O
i	O
.	O
e	O
.	O
rno	O
-	O
miR	O
-	O
199a	O
-	O
5p	O
,	O
-	O
214	O
and	O
-	O
146b	O
miRNAs	O
for	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qPCR	O
)	O
assays	O
.	O

We	O
also	O
chose	O
rno	O
-	O
miR	O
-	O
31	O
as	O
another	O
candidate	O
for	O
qPCR	O
due	O
to	O
its	O
previous	O
verification	O
in	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
rat	B-OG
model	O
[	O
34	O
].	O

Taqman	O
assays	O
showed	O
increased	O
expression	O
of	O
rno	O
-	O
miR	O
-	O
199a	O
-	O
5p	O
,	O
-	O
214	O
,	O
-	O
146b	O
and	O
-	O
31	O
in	O
diseased	O
kidneys	O
(	O
Figure	O
4	O
).	O

These	O
results	O
confirmed	O
the	O
outcomes	O
of	O
miRNA	O
microarrays	O
profiling	O
for	O
selected	O
miRNAs	O
(	O
Figure	O
3	O
).	O

TaqMan	O
assays	O
for	O
miRNAs	O
.	O

The	O
figure	O
shows	O
high	O
abundance	O
of	O
transcripts	O
of	O
rno	O
-	O
miR	O
-	O
146b	O
,	O
-	O
199a	O
-	O
5p	O
,	O
-	O
214	O
and	O
-	O
31	O
in	O
PKD	B-DS
/	O
Mhm	O
(	O
cy	O
/+)	O
rat	B-OG
model	O
as	O
observed	O
on	O
microarrays	O
.	O
‘***’	O
indicates	O
for	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
.	O

The	O
black	O
and	O
white	O
box	O
plots	O
represent	O
cystic	O
and	O
healthy	O
kidneys	O
.	O

Putative	O
Targets	O
Identification	O
and	O
Pathway	O
Enrichment	O
Analysis	O
of	O
8	O
Up	O
-	O
regulated	O
miRNAs	O
in	O
PKD	B-DS

Approximately	O
33	O
,	O
500	O
miRNA	O
-	O
target	O
interaction	O
pairs	O
were	O
observed	O
between	O
8	O
up	O
-	O
regulated	O
miRNAs	O
and	O
all	O
known	O
genes	O
of	O
rat	B-OG
by	O
performing	O
an	O
in	O
-	O
silico	O
screening	O
using	O
miRWalk	O
database	O
.	O

Many	O
genes	O
were	O
identified	O
as	O
the	O
putative	O
target	O
of	O
these	O
8	O
up	O
-	O
regulated	O
miRNAs	O
.	O

Moreover	O
,	O
about	O
37	O
,	O
306	O
binding	O
pairs	O
were	O
also	O
obtained	O
on	O
8	O
miRNAs	O
by	O
interrogating	O
the	O
comparative	O
platform	O
of	O
miRWalk	O
database	O
[	O
31	O
]	O
(	O
Table	O
S6	O
).	O

More	O
than	O
100	O
common	O
genes	O
(	O
such	O
as	O
Stat3	B-GP
,	O
Tp53	B-GP
,	O
Ccnl1	B-GP
and	O
Bmp3	B-GP
)	O
were	O
predicted	O
as	O
the	O
putative	O
targets	O
of	O
these	O
8	O
miRNAs	O
by	O
6	O
different	O
algorithms	O
.	O

To	O
determine	O
the	O
possible	O
roles	O
of	O
these	O
8	O
up	O
-	O
regulated	O
miRNAs	O
in	O
different	O
pathways	O
,	O
we	O
selected	O
only	O
those	O
transcripts	O
that	O
were	O
predicted	O
by	O
at	O
least	O
2	O
algorithms	O
.	O

Then	O
,	O
the	O
significantly	O
enriched	O
pathways	O
were	O
evaluated	O
using	O
a	O
customised	O
R	O
-	O
script	O
.	O

A	O
total	O
of	O
107	O
significantly	O
enriched	O
pathways	O
were	O
found	O
on	O
the	O
putative	O
target	O
genes	O
of	O
these	O
8	O
miRNAs	O
(	O
Table	O
S7	O
).	O

Of	O
note	O
,	O
61	O
pathways	O
(	O
e	O
.	O
g	O
.,	O
metabolic	O
,	O
Wnt	B-GP
signaling	O
,	O
adipocytokine	B-GP
signaling	O
,	O
calcium	O
signaling	O
,	O
Tgf	B-GP
-	I-GP
β	I-GP
signaling	O
and	O
cell	O
cycle	O
)	O
showed	O
a	O
strong	O
overlap	O
with	O
the	O
pathways	O
resulting	O
from	O
3	O
,	O
333	O
deregulated	O
genes	O
in	O
PKD	B-DS
.	O

Possible	O
Interactions	O
Among	O
Deregulated	O
Genes	O
and	O
Up	O
-	O
regulated	O
miRNAs	O

The	O
miRWalk	O
algorithm	O
was	O
adopted	O
to	O
identify	O
the	O
putative	O
potential	O
binding	O
sites	O
between	O
deregulated	O
genes	O
and	O
miRNAs	O
during	O
PKD	B-DS
.	O

More	O
than	O
13	O
,	O
880	O
mRNA	O
-	O
miRNA	O
interactions	O
were	O
observed	O
.	O

The	O
interaction	O
pairs	O
were	O
decreased	O
to	O
5	O
,	O
472	O
,	O
when	O
a	O
significant	O
threshold	O
cut	O
-	O
off	O
p	O
-	O
value	O
was	O
set	O
to	O
0	O
.	O
05	O
.	O
Table	O
3	O
shows	O
an	O
overview	O
of	O
binding	O
seeds	O
of	O
8	O
miRNAs	O
that	O
were	O
predicted	O
within	O
the	O
different	O
regions	O
of	O
3	O
,	O
333	O
deregulated	O
genes	O
.	O

Notably	O
,	O
miR	O
-	O
214	O
was	O
predicted	O
to	O
anneal	O
with	O
the	O
maximum	O
number	O
of	O
significant	O
genes	O
(	O
1	O
,	O
118	O
i	O
.	O
e	O
.	O
583	O
down	O
-	O
and	O
535	O
up	O
-	O
regulated	O
)	O
and	O
its	O
seeds	O
were	O
more	O
specific	O
to	O
down	O
-	O
regulated	O
genes	O
(	O
Table	O
3	O
).	O

The	O
miR	O
-	O
34a	O
was	O
determined	O
as	O
the	O
2nd	O
highest	O
targeting	O
miRNA	O
which	O
can	O
anneal	O
with	O
693	O
genes	O
.	O

Distribution	O
of	O
binding	O
sites	O
of	O
8	O
miRNAs	O
within	O
3	O
,	O
333	O
deregulated	O
genes	O
.	O

Down	O
-	O
regulated	O
genes	O
(	O
sites	O
/	O
genes	O
)	O

Up	O
-	O
regulated	O
genes	O
(	O
sites	O
/	O
genes	O
)	O

miRNAs	O

5UTR	O

CDS	O

3UTR	O

Enrichment	O
(	O
p	O
-	O
value	O
)	O

5UTR	O

CDS	O

3UTR	O

Enrichment	O
(	O
p	O
-	O
value	O
)	O

miR	O
-	O
214	O

101	O
/	O
71	O

438	O
/	O
322	O

268	O
/	O
190	O

9	O
.	O
77E	O
−	O
15	O

60	O
/	O
53	O

412	O
/	O
313	O

223	O
/	O
169	O

2	O
.	O
43E	O
−	O
09	O

miR	O
-	O
34a	O

43	O
/	O
34	O

249	O
/	O
188	O

155	O
/	O
124	O

7	O
.	O
42E	O
−	O
05	O

41	O
/	O
37	O

253	O
/	O
189	O

152	O
/	O
121	O

2	O
.	O
14E	O
−	O
12	O

miR	O
-	O
199a	O
-	O
5p	O

33	O
/	O
28	O

176	O
/	O
152	O

170	O
/	O
128	O

0	O
.	O
003	O

29	O
/	O
24	O

164	O
/	O
129	O

139	O
/	O
93	O

Non	O
-	O
significant	O

miR	O
-	O
146b	O

35	O
/	O
28	O

177	O
/	O
128	O

147	O
/	O
105	O

1	O
.	O
17E	O
−	O
08	O

19	O
/	O
16	O

144	O
/	O
107	O

116	O
/	O
84	O

0	O
.	O
003	O

miR	O
-	O
503	O

46	O
/	O
50	O

106	O
/	O
119	O

151	O
/	O
56	O

0	O
.	O
0002	O

47	O
/	O
61	O

63	O
/	O
119	O

164	O
/	O
55	O

2E	O
−	O
06	O

miR	O
-	O
31	O

62	O
/	O
34	O

146	O
/	O
77	O

65	O
/	O
109	O

1	O
.	O
05E	O
−	O
05	O

67	O
/	O
40	O

142	O
/	O
48	O

60	O
/	O
126	O

8	O
.	O
54E	O
−	O
07	O

miR	O
-	O
132	O

17	O
/	O
13	O

71	O
/	O
59	O

114	O
/	O
94	O

0	O
.	O
01	O

19	O
/	O
17	O

55	O
/	O
42	O

125	O
/	O
96	O

0	O
.	O
0007	O

miR	O
-	O
21	O

9	O
/	O
7	O

41	O
/	O
34	O

65	O
/	O
55	O

Non	O
-	O
significant	O

9	O
/	O
4	O

35	O
/	O
27	O

53	O
/	O
42	O

Non	O
-	O
significant	O

To	O
further	O
support	O
these	O
findings	O
,	O
we	O
accomplished	O
a	O
binding	O
sites	O
overrepresentation	O
analysis	O
in	O
which	O
rno	O
-	O
miR	O
-	O
34a	O
(	O
p	O
-	O
value	O
=	O
2	O
.	O
14e	O
−	O
12	O
),	O
-	O
31	O
,	O
-	O
503	O
,	O
-	O
214	O
,	O
-	O
132	O
and	O
-	O
146b	O
binding	O
sites	O
were	O
observed	O
as	O
significantly	O
enriched	O
within	O
up	O
-	O
regulated	O
genes	O
(	O
Table	O
3	O
),	O
whereas	O
rno	O
-	O
miR	O
-	O
214	O
(	O
p	O
-	O
value	O
=	O
9	O
.	O
77e	O
−	O
15	O
),	O
-	O
146b	O
,	O
-	O
31	O
,	O
-	O
34a	O
,	O
-	O
503	O
,	O
-	O
199a	O
-	O
5p	O
and	O
-	O
132	O
were	O
determined	O
as	O
overrepresented	O
within	O
down	O
-	O
regulated	O
genes	O
(	O
Table	O
3	O
).	O

The	O
rno	O
-	O
miR	O
-	O
34a	O
and	O
-	O
214	O
were	O
noticed	O
as	O
the	O
highly	O
overrepresented	O
miRNAs	O
within	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
,	O
respectively	O
.	O

These	O
findings	O
support	O
our	O
previous	O
assumption	O
in	O
which	O
we	O
found	O
that	O
rno	O
-	O
miR	O
-	O
214	O
binding	O
sites	O
are	O
abundantly	O
present	O
within	O
down	O
-	O
regulated	O
genes	O
.	O

Furthermore	O
,	O
over	O
8	O
,	O
700	O
interactions	O
were	O
obtained	O
by	O
querying	O
the	O
comparative	O
platform	O
of	O
miRWalk	O
database	O
(	O
at	O
least	O
2	O
algorithms	O
).	O

33	O
(	O
17	O
down	O
-	O
regulated	O
:	O
e	O
.	O
g	O
.,	O
Acsl1	B-GP
,	O
Atp2a3	B-GP
,	O
and	O
Eif4a2	B-GP
and	O
16	O
up	O
-	O
regulated	O
:	O
such	O
as	O
Tp53	B-GP
,	O
Stat3	B-GP
and	O
Il34	B-GP
)	O
genes	O
were	O
predicted	O
as	O
target	O
of	O
these	O
8	O
miRNAs	O
by	O
6	O
different	O
algorithms	O
.	O

Moreover	O
,	O
Fn1	B-GP
was	O
predicted	O
to	O
be	O
a	O
putative	O
target	O
of	O
miR	O
-	O
146b	O
(	O
5	O
programs	O
)	O
and	O
miR	O
-	O
503	O
,	O
-	O
214	O
,	O
-	O
31	O
,	O
-	O
34a	O
,	O
-	O
199a	O
-	O
5p	O
,	O
and	O
-	O
132	O
(	O
2	O
programs	O
).	O

These	O
results	O
indicate	O
that	O
the	O
expression	O
of	O
3	O
,	O
333	O
deregulated	O
genes	O
could	O
be	O
modulated	O
by	O
these	O
8	O
up	O
-	O
regulated	O
miRNAs	O
in	O
PKD	B-DS
.	O

Impact	O
of	O
8	O
miRNAs	O
on	O
Dysregulated	O
Pathways	O
of	O
3	O
,	O
333	O
Deregulated	O
Genes	O

We	O
wanted	O
to	O
explore	O
how	O
many	O
members	O
of	O
overrepresented	O
pathways	O
are	O
the	O
putative	O
targets	O
of	O
these	O
8	O
up	O
-	O
regulated	O
miRNAs	O
and	O
how	O
their	O
possible	O
binding	O
sites	O
could	O
promote	O
cysts	B-DS
formation	O
in	O
healthy	O
kidneys	O
.	O

Toward	O
this	O
task	O
,	O
we	O
determined	O
over	O
700	O
and	O
150	O
putative	O
binding	O
seeds	O
(	O
7	O
to	O
12	O
nt	O
long	O
)	O
of	O
these	O
8	O
miRNAs	O
within	O
the	O
different	O
regions	O
of	O
the	O
members	O
engaged	O
with	O
significantly	O
up	O
-	O
and	O
down	O
-	O
regulated	O
pathways	O
.	O

Few	O
examples	O
include	O
;	O
rno	O
-	O
miR	O
-	O
214	O
can	O
target	O
Itgb4	B-GP
(	O
focal	O
adhesion	O
,	O
ECM	B-GP
-	I-GP
receptor	I-GP
and	O
actin	B-GP
cytoskeleton	O
),	O
Ccl19	B-GP
(	O
chemokine	B-GP
signaling	O
),	O
Mcm4	B-GP
(	O
cell	O
cycle	O
and	O
DNA	O
replication	O
)	O
and	O
Tbl1x	B-GP
(	O
Wnt	B-GP
signaling	O
).	O

Table	O
4	O
depicts	O
a	O
comprehensive	O
atlas	O
of	O
the	O
possible	O
binding	O
sites	O
of	O
these	O
8	O
miRNAs	O
within	O
the	O
deregulated	O
members	O
of	O
differentially	O
regulated	O
pathways	O
.	O

Notably	O
,	O
rno	O
-	O
miR	O
-	O
214	O
was	O
predicted	O
to	O
have	O
maximum	O
number	O
of	O
binding	O
sites	O
within	O
the	O
representative	O
members	O
of	O
down	O
-	O
regulated	O
pathways	O
,	O
whereas	O
,	O
rno	O
-	O
miR	O
-	O
34a	O
was	O
detected	O
as	O
miRNA	O
hub	O
having	O
maximum	O
number	O
of	O
interactions	O
within	O
the	O
members	O
of	O
up	O
-	O
regulated	O
pathways	O
.	O

Overview	O
of	O
binding	O
site	O
predictions	O
of	O
8	O
miRNAs	O
within	O
the	O
representative	O
members	O
of	O
deregulated	O
pathways	O
.	O

Terms	O

miR	O
-	O
132	O

miR	O
-	O
146b	O

miR	O
-	O
199a	O
-	O
5p	O

miR	O
-	O
21	O

miR	O
-	O
214	O

miR	O
-	O
31	O

miR	O
-	O
34a	O

miR	O
-	O
503	O

N	O
(	O
interaction	O
)	O

Up	O
-	O
regulated	O
pathways	O

MAPK	B-GP
signaling	O

5	O

11	O

7	O

3	O

21	O

9	O

16	O

7	O

79	O

Focal	O
adhesion	O

5	O

8	O

6	O

1	O

18	O

12	O

17	O

7	O

74	O

Actin	B-GP
cytoskeleton	O

5	O

9	O

3	O

2	O

11	O

6	O

18	O

6	O

60	O

Cell	O
cycle	O

2	O

4	O

6	O

3	O

18	O

7	O

12	O

6	O

58	O

Cytokine	B-GP
-	O
cytokine	B-GP

2	O

4	O

12	O

2	O

10	O

6	O

12	O

6	O

54	O

Chemokine	B-GP
signaling	O

0	O

5	O

5	O

2	O

14	O

6	O

11	O

9	O

52	O

CAMs	O

11	O

4	O

2	O

2	O

11	O

1	O

7	O

8	O

46	O

ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O

3	O

3	O

3	O

0	O

14	O

5	O

9	O

3	O

40	O

Wnt	B-GP
signaling	O

3	O

1	O

2	O

0	O

9	O

6	O

12	O

6	O

39	O

VSMC	O
signaling	O

1	O

1	O

5	O

1	O

7	O

6	O

7	O

1	O

29	O

p53	O
signaling	O

2	O

0	O

2	O

1	O

9	O

2	O

8	O

3	O

27	O

Calcium	O
signaling	O

0	O

3	O

4	O

1	O

4	O

2	O

7	O

2	O

23	O

Apoptosis	O

1	O

2	O

3	O

2	O

5	O

3	O

5	O

2	O

23	O

DNA	O
replication	O

1	O

0	O

2	O

3	O

7	O

2	O

5	O

2	O

22	O

Jak	O
-	O
STAT	O

3	O

2	O

3	O

1	O

5	O

2	O

3	O

2	O

21	O

TGF	O
-	O
beta	O

0	O

0	O

4	O

0	O

4	O

3	O

4	O

1	O

16	O

Phosphatidylinositol	O

0	O

2	O

6	O

0	O

3	O

2	O

2	O

0	O

15	O

Significantly	O
down	O
-	O
regulated	O
pathways	O

V	O
.	O
L	O
.	O
I	O
.	O
degradation	O

9	O

6	O

8	O

4	O

8	O

4	O

9	O

6	O

54	O

Fatty	O
acid	O
metabolism	O

4	O

2	O

6	O

3	O

7	O

1	O

6	O

3	O

32	O

Propanoate	O
metabolism	O

6	O

2	O

5	O

3	O

3	O

2	O

2	O

2	O

25	O

Citrate	O
cycle	O
(	O
TCA	O
cycle	O
)	O

2	O

4	O

2	O

1	O

5	O

1	O

2	O

1	O

18	O

Pantothenate	O
and	O
CoA	O

0	O

5	O

1	O

1	O

5	O

1	O

4	O

1	O

18	O

Discussion	O

Parallel	O
mRNA	O
and	O
miRNA	O
microarray	O
profiling	O
in	O
PKD	B-DS
revealed	O
3	O
,	O
333	O
significantly	O
deregulated	O
genes	O
and	O
8	O
up	O
-	O
regulated	O
miRNAs	O
,	O
respectively	O
.	O

The	O
expression	O
patterns	O
of	O
nephron	O
segment	O
-	O
specific	O
genes	O
(	O
e	O
.	O
g	O
.,	O
Pck1	B-GP
,	O
Kcnj1a	B-GP
and	O
Scnn1g	B-GP
)	O
were	O
down	O
-	O
regulated	O
.	O

Of	O
note	O
,	O
we	O
found	O
up	O
-	O
regulation	O
of	O
multiple	O
developmental	O
genes	O
(	O
e	O
.	O
g	O
.,	O
Bmp1	B-GP
,	O
Mmp12	B-GP
and	O
kcnj8	B-GP
),	O
transcription	B-GP
factors	I-GP
(	O
TFs	B-GP
)	O
(	O
e	O
.	O
g	O
.,	O
Myc	B-GP
,	O
Ap1	B-GP
,	O
Stat3	B-GP
and	O
Cux1	B-GP
)	O
and	O
integrins	B-GP
(	O
e	O
.	O
g	O
.,	O
Itga1	B-GP
,	O
2b	O
,	O
a3	O
,	O
5	O
and	O
b11	O
).	O

Many	O
of	O
these	O
members	O
are	O
closely	O
related	O
to	O
ureteric	O
bud	O
formation	O
,	O
outgrowth	O
and	O
branching	O
during	O
metanephric	O
kidney	O
development	O
[	O
28	O
],	O
[	O
29	O
],	O
[	O
40	O
].	O

On	O
the	O
other	O
hand	O
,	O
up	O
-	O
regulation	O
of	O
genes	O
i	O
.	O
e	O
.	O
Bmp1	B-GP
,	O
Tgfβ1	B-GP
,	O
Tgfβ2	B-GP
,	O
Tgfβr1	B-GP
and	O
Tgfβr2	B-GP
suggest	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
).	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
re	O
-	O
activation	O
of	O
signaling	O
pathways	O
for	O
renal	O
development	O
and	O
repair	O
in	O
PKD	B-DS
/	O
Mhm	O
renal	B-DS
cysts	I-DS
.	O

Further	O
,	O
the	O
previous	O
studies	O
of	O
the	O
cystic	B-DS
kidneys	I-DS
implicated	O
TGF	B-GP
-	I-GP
β	I-GP
in	O
renal	O
cell	O
hypertrophy	O
and	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
deposition	O
in	O
diabetic	B-DS
nephropathy	I-DS
[	O
41	O
]	O
and	O
PKD	B-DS
[	O
42	O
].	O

The	O
expression	O
of	O
ECM	O
components	O
such	O
as	O
Cthrc1	B-GP
,	O
Fn1	B-GP
and	O
Collagens	B-GP
was	O
significantly	O
higher	O
in	O
PKD	B-DS
.	O

MYC	B-GP
gene	O
is	O
often	O
found	O
up	O
-	O
regulated	O
in	O
human	B-OG
ADPKD	B-DS
[	O
17	O
]	O
and	O
we	O
also	O
detected	O
the	O
similar	O
expression	O
in	O
our	O
study	O
.	O
MYC	B-GP
is	O
known	O
to	O
be	O
involved	O
in	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
differentiation	O
and	O
neoplasia	B-DS
[	O
18	O
].	O

Of	O
note	O
,	O
in	O
the	O
kidneys	O
of	O
PKD	B-DS
patients	O
,	O
both	O
apoptosis	O
and	O
proliferation	O
are	O
associated	O
with	O
increased	O
expression	O
of	O
Myc	B-GP
[	O
43	O
].	O

Interestingly	O
,	O
Pla2g2a	B-GP
,	O
Pla2g4a	B-GP
and	O
Ptgfrn	B-GP
genes	O
(	O
involved	O
in	O
cAMP	O
mediated	O
signaling	O
and	O
calcium	O
regulation	O
)	O
were	O
also	O
up	O
-	O
regulated	O
,	O
while	O
negative	O
regulators	O
(	O
such	O
as	O
Rgs9	B-GP
,	O
Rgs12	B-GP
and	O
Rgs14	B-GP
)	O
of	O
GPCR	B-GP
signaling	O
were	O
down	O
-	O
regulated	O
.	O

These	O
transcriptomic	O
changes	O
suggest	O
a	O
modification	O
in	O
GPCR	B-GP
signaling	O
that	O
may	O
result	O
in	O
the	O
regulation	O
of	O
cAMP	O
and	O
calcium	O
signaling	O
in	O
PKD	B-DS
.	O

We	O
also	O
observed	O
up	O
-	O
regulation	O
of	O
Adcy2	B-GP
.	O

This	O
gene	O
may	O
elevate	O
the	O
cAMP	O
signaling	O
in	O
cysts	B-DS
which	O
further	O
leads	O
to	O
proliferation	O
[	O
44	O
].	O

An	O
increased	O
in	O
the	O
cAMP	O
production	O
has	O
previously	O
been	O
shown	O
to	O
stimulate	O
renal	O
cystic	O
epithelial	O
proliferation	O
in	O
PKD	B-DS
[	O
44	O
].	O

Notably	O
,	O
the	O
additional	O
genes	O
(	O
down	O
-	O
regulated	O
:	O
Nphp1	B-GP
,	O
Mks1	B-GP
and	O
Bbs4	B-GP
;	O
up	O
-	O
regulated	O
:	O
Pkd2	B-GP
,	O
Nphp4	B-GP
,	O
Bbs7	B-GP
,	O
Ofd1	B-GP
and	O
Pdgfra	B-GP
)	O
associated	O
with	O
ciliary	O
function	O
or	O
renal	B-DS
cystic	I-DS
disorders	I-DS
were	O
also	O
differentially	O
expressed	O
in	O
diseased	O
kidneys	O
.	O

Abnormal	O
expression	O
of	O
Pkd2	B-GP
leads	O
to	O
disrupt	O
multiple	O
biological	O
processes	O
(	O
e	O
.	O
g	O
.,	O
cell	O
division	O
,	O
proliferation	O
,	O
and	O
deregulated	O
cell	O
-	O
matrix	O
and	O
/	O
or	O
cell	O
-	O
cell	O
interactions	O
).	O

The	O
up	O
-	O
regulation	O
of	O
similar	O
processes	O
such	O
as	O
cell	O
cycle	O
,	O
proliferation	O
,	O
ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O
and	O
focal	O
adhesion	O
were	O
also	O
noticed	O
in	O
PKD	B-DS
.	O

Moreover	O
,	O
12	O
pathways	O
(	O
such	O
as	O
focal	O
adhesion	O
,	O
cell	O
cycle	O
and	O
ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O
)	O
were	O
identified	O
as	O
significantly	O
up	O
-	O
regulated	O
in	O
PKD	B-DS
.	O

Previous	O
studies	O
suggested	O
that	O
an	O
aberrant	O
activation	O
of	O
these	O
pathways	O
plays	O
a	O
role	O
in	O
ADPKD	B-DS
.	O

Therefore	O
,	O
these	O
genes	O
might	O
be	O
considered	O
as	O
potential	O
markers	O
for	O
the	O
activation	O
of	O
complex	O
network	O
processes	O
that	O
may	O
promote	O
cysts	B-DS
in	O
PKD	B-DS
animals	B-OG
.	O

Additionally	O
,	O
we	O
also	O
obtained	O
five	O
significantly	O
down	O
-	O
regulated	O
metabolic	O
pathways	O
(	O
Table	O
1	O
).	O

miRNAs	O
have	O
emerged	O
as	O
mediators	O
of	O
gene	O
expression	O
.	O

They	O
direct	O
the	O
regulation	O
of	O
cellular	O
processes	O
include	O
;	O
differentiation	O
,	O
proliferation	O
,	O
cell	O
-	O
cell	O
interaction	O
,	O
cell	O
death	O
,	O
metabolism	O
and	O
many	O
diseases	O
.	O

Another	O
important	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
possible	O
regulatory	O
role	O
of	O
miRNAs	O
in	O
ADPKD	B-DS
.	O

Several	O
potential	O
binding	O
sites	O
were	O
observed	O
between	O
3	O
,	O
333	O
deregulated	O
genes	O
and	O
8	O
up	O
-	O
regulated	O
miRNAs	O
in	O
PKD	B-DS
using	O
the	O
miRWalk	O
database	O
[	O
31	O
].	O

A	O
few	O
potential	O
interactions	O
are	O
:	O
rno	O
-	O
miR	O
-	O
214	O
,	O
-	O
31	O
,	O
-	O
199a	O
-	O
5p	O
,	O
-	O
21	O
,	O
-	O
34a	O
and	O
-	O
132	O
were	O
predicted	O
to	O
target	O
several	O
down	O
-	O
regulated	O
TFs	B-GP
such	O
as	O
Hnf1α	B-GP
,	O
Nfatc4	B-GP
and	O
Glis2	B-GP
.	O

These	O
TFs	B-GP
may	O
play	O
a	O
crucial	O
role	O
(	O
either	O
positive	O
or	O
negative	O
regulators	O
)	O
in	O
the	O
promoter	O
region	O
of	O
deregulated	O
genes	O
in	O
the	O
cystic	B-DS
kidneys	I-DS
.	O

Our	O
findings	O
show	O
an	O
agreement	O
with	O
a	O
previous	O
study	O
that	O
states	O
miRNAs	O
often	O
control	O
the	O
expression	O
of	O
key	O
genes	O
by	O
annealing	O
within	O
the	O
sequence	O
of	O
upstream	O
flanking	O
regions	O
’	O
regulators	O
(	O
repressors	O
or	O
enhancers	O
)	O
[	O
45	O
].	O

The	O
rno	O
-	O
miR	O
-	O
199a	O
-	O
5p	O
/	O
214	O
transcript	O
was	O
previously	O
reported	O
during	O
development	O
[	O
46	O
]	O
and	O
epithelial	B-DS
ovarian	I-DS
cancer	I-DS
cells	O
[	O
47	O
].	O

The	O
implications	O
of	O
miR	O
-	O
146a	O
(	O
but	O
not	O
miR	O
-	O
146b	O
)	O
have	O
been	O
shown	O
in	O
chronic	B-DS
renal	I-DS
inflammation	I-DS
[	O
48	O
],	O
human	B-OG
renal	B-DS
cell	I-DS
carcinoma	I-DS
[	O
49	O
]	O
and	O
retinoic	O
acid	O
induction	O
in	O
acute	B-DS
promyelocytic	I-DS
leukemia	I-DS
[	O
50	O
].	O

The	O
miR	O
-	O
21	O
has	O
been	O
reported	O
to	O
promote	O
mostly	O
fibrosis	O
[	O
51	O
],	O
to	O
correlate	O
lower	O
kidney	B-DS
cancer	I-DS
survival	O
[	O
52	O
]	O
and	O
to	O
modulate	O
cell	O
apoptosis	O
in	O
renal	B-DS
cell	I-DS
carcinoma	I-DS
[	O
53	O
].	O

The	O
rno	O
-	O
miR	O
-	O
31	O
is	O
the	O
only	O
miRNAs	O
that	O
has	O
been	O
previously	O
reported	O
in	O
PKD	B-DS
[	O
34	O
].	O

Of	O
note	O
,	O
7	O
of	O
these	O
8	O
miRNAs	O
have	O
not	O
been	O
previously	O
reported	O
in	O
PKD	B-DS
.	O

miRNAs	O
direct	O
the	O
temporal	O
changes	O
in	O
the	O
expression	O
of	O
the	O
representative	O
members	O
of	O
key	O
signaling	O
pathways	O
,	O
as	O
these	O
small	O
changes	O
may	O
alter	O
the	O
responsiveness	O
of	O
cells	O
to	O
signaling	O
molecules	O
(	O
such	O
as	O
TGF	B-GP
-	I-GP
β	I-GP
,	O
Wnt	B-GP
,	O
Notch	B-GP
,	O
and	O
EGF	B-GP
)	O
[	O
54	O
].	O

Once	O
an	O
inhibitor	O
(	O
e	O
.	O
g	O
.,	O
Hnf1α	B-GP
,	O
Hnf4α	B-GP
,	O
Glis2	B-GP
and	O
Sip1	B-GP
)	O
of	O
signaling	O
networks	O
is	O
down	O
-	O
regulated	O
by	O
one	O
or	O
more	O
miRNAs	O
,	O
these	O
miRNAs	O
then	O
act	O
as	O
a	O
positive	O
regulator	O
which	O
further	O
amplifies	O
the	O
expression	O
of	O
many	O
genes	O
engaged	O
with	O
human	B-OG
pathologies	O
.	O

Such	O
possible	O
regulatory	O
roles	O
were	O
also	O
observed	O
in	O
PKD	B-DS
.	O

For	O
example	O
,	O
the	O
putative	O
seeds	O
of	O
miR	O
-	O
199a	O
-	O
5p	O
(	O
9nt	O
long	O
seed	O
)	O
and	O
miR	O
-	O
34a	O
(	O
7nt	O
long	O
seed	O
)	O
within	O
3	O
′-	O
UTR	O
region	O
of	O
p27	B-GP
(	O
Cdkn1b	B-GP
)	O
suggest	O
the	O
possibility	O
that	O
this	O
gene	O
may	O
be	O
down	O
-	O
regulated	O
by	O
these	O
2	O
miRNAs	O
in	O
PKD	B-DS
.	O

The	O
p27	B-GP
is	O
a	O
CDKs	B-GP
(	O
cyclin	B-GP
-	I-GP
dependent	I-GP
kinases	I-GP
)	O
inhibitor	O
of	O
the	O
cell	O
cycle	O
at	O
G1	O
phase	O
(	O
Cdk2	B-GP
/	O
Ccne2	B-GP
complex	O
).	O

Furthermore	O
,	O
Apc	B-GP
(	O
down	O
-	O
regulated	O
)	O
was	O
predicted	O
as	O
a	O
putative	O
target	O
of	O
miR	O
-	O
214	O
with	O
a	O
seed	O
of	O
10nt	O
long	O
.	O
Apc	B-GP
(	O
an	O
E3	B-GP
ubiquitin	I-GP
ligase	I-GP
)	O
gene	O
stimulates	O
the	O
cell	O
cycle	O
progression	O
by	O
degrading	O
checkpoint	O
proteins	O
such	O
as	O
Ccnb1	B-GP
(	O
up	O
-	O
regulated	O
).	O

Moreover	O
,	O
three	O
miRNAs	O
(	O
miR	O
-	O
199a	O
-	O
5p	O
,	O
-	O
214	O
and	O
-	O
132	O
)	O
were	O
predicted	O
to	O
anneal	O
within	O
3	O
′-	O
UTR	O
of	O
Rb1	B-GP
(	O
down	O
-	O
regulated	O
)	O
which	O
is	O
also	O
a	O
cell	O
cycle	O
inhibitor	O
.	O

Several	O
other	O
down	O
-	O
regulated	O
genes	O
such	O
as	O
Hes6	B-GP
(	O
inhibits	O
cell	O
proliferation	O
),	O
Rbl2	B-GP
(	O
tumour	B-DS
suppressor	O
and	O
inhibitor	O
of	O
E2F	B-GP
target	O
genes	O
)	O
and	O
Id1	B-GP
(	O
a	O
bHLH	B-GP
transcription	I-GP
factor	I-GP
that	O
regulates	O
cell	O
proliferation	O
by	O
supressing	O
p21	B-GP
or	O
Cdkn1a	B-GP
,	O
a	O
CDKs	B-GP
inhibitor	O
)	O
were	O
also	O
observed	O
as	O
the	O
putative	O
targets	O
of	O
rno	O
-	O
miR	O
-	O
503	O
,	O
-	O
214	O
and	O
-	O
146b	O
and	O
-	O
503	O
.	O

Of	O
note	O
,	O
Ift88	B-GP
and	O
Ift122	B-GP
were	O
determined	O
as	O
the	O
possible	O
targets	O
of	O
rno	O
-	O
miR	O
-	O
199a	O
-	O
5p	O
and	O
-	O
214	O
.	O

These	O
genes	O
were	O
noticed	O
as	O
significantly	O
down	O
-	O
regulated	O
in	O
PKD	B-DS
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
a	O
small	O
interfering	O
in	O
Ift88	B-GP
accelerates	O
cell	O
cycle	O
progression	O
with	O
an	O
increase	O
in	O
proliferation	O
(	O
reviewed	O
in	O
[	O
55	O
]).	O

Our	O
putative	O
findings	O
suggest	O
that	O
these	O
8	O
miRNAs	O
could	O
mediate	O
the	O
down	O
-	O
regulation	O
of	O
the	O
crucial	O
checkpoint	O
genes	O
(	O
inhibitors	O
)	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
proliferation	O
and	O
may	O
result	O
in	O
the	O
aberrant	O
activation	O
of	O
these	O
processes	O
which	O
may	O
lead	O
to	O
PKD	B-DS
.	O

Moreover	O
,	O
the	O
importance	O
of	O
apoptosis	O
has	O
been	O
highlighted	O
in	O
which	O
the	O
inactivation	O
of	O
apoptosis	O
inhibitors	O
such	O
as	O
Bcl2	B-GP
causes	O
CKD	B-DS
[	O
16	O
].	O

3	O
miRNAs	O
(	O
miR	O
-	O
34a	O
,	O
-	O
21	O
and	O
-	O
503	O
)	O
were	O
predicted	O
to	O
target	O
Bcl2	B-GP
gene	O
(	O
down	O
-	O
regulated	O
).	O

These	O
3	O
miRNAs	O
may	O
decrease	O
the	O
expression	O
of	O
Bcl2	B-GP
and	O
could	O
cause	O
PKD	B-DS
via	O
abnormal	O
activation	O
of	O
apoptosis	O
.	O

Interestingly	O
,	O
other	O
down	O
-	O
regulated	O
genes	O
that	O
encode	O
for	O
cilia	O
and	O
PCP	O
signaling	O
proteins	O
such	O
as	O
Tsc2	B-GP
,	O
Nek9	B-GP
,	O
Bbs4	B-GP
,	O
Mks1	B-GP
,	O
Dvl1	B-GP
,	O
Pkd2	B-GP
,	O
Sod2	B-GP
and	O
Wnt10a	B-GP
were	O
also	O
determined	O
as	O
the	O
putative	O
targets	O
of	O
these	O
8	O
up	O
-	O
regulated	O
miRNAs	O
.	O

Altogether	O
,	O
it	O
can	O
be	O
concluded	O
that	O
these	O
mRNA	O
:	O
miRNA	O
interactions	O
may	O
result	O
in	O
ADPKD	B-DS
via	O
the	O
dysregulation	O
of	O
cell	O
cycle	O
,	O
differentiation	O
,	O
orientation	O
,	O
proliferation	O
and	O
apoptosis	O
.	O

The	O
abnormalities	O
in	O
these	O
pathways	O
have	O
previously	O
been	O
reported	O
in	O
human	B-OG
ADPKD	B-DS
[	O
17	O
],	O
[	O
56	O
],	O
[	O
57	O
].	O

Interestingly	O
,	O
several	O
potential	O
interactions	O
between	O
8	O
up	O
-	O
regulated	O
miRNAs	O
and	O
6	O
down	O
-	O
regulated	O
aquaporins	B-GP
(	O
AQPs	B-GP
)	O
genes	O
were	O
observed	O
for	O
examples	O
:	O
miR	O
-	O
199a	O
-	O
5p	O
,	O
-	O
214	O
and	O
-	O
503	O
can	O
anneal	O
to	O
Aqp1	B-GP
and	O
Aqp12a	B-GP
with	O
octamer	O
seeds	O
;	O
and	O
Aqp4	B-GP
has	O
multiple	O
9nt	O
long	O
binding	O
sites	O
for	O
miR	O
-	O
132	O
.	O

These	O
binding	O
sites	O
may	O
explain	O
why	O
the	O
kidneys	O
of	O
PKD	B-DS
/	O
Mhm	O
rats	B-OG
have	O
enlarged	O
cysts	B-DS
.	O

Since	O
,	O
AQPs	B-GP
are	O
the	O
most	O
important	O
water	O
channel	O
for	O
transepithelial	O
water	O
permeability	O
,	O
and	O
exit	O
pathway	O
for	O
water	O
that	O
enters	O
the	O
cell	O
[	O
58	O
]	O
and	O
most	O
importantly	O
their	O
knocking	O
out	O
resulted	O
in	O
renal	B-DS
failure	I-DS
,	O
which	O
is	O
similar	O
to	O
PKD	B-DS
[	O
15	O
],	O
[	O
59	O
],	O
[	O
60	O
].	O

These	O
miRNA	O
-	O
mediated	O
down	O
-	O
regulations	O
could	O
abolish	O
these	O
exit	O
doors	O
.	O

Notably	O
,	O
these	O
interactions	O
have	O
not	O
been	O
previously	O
described	O
in	O
ADPKD	B-DS
.	O

Also	O
,	O
miR	O
-	O
214	O
and	O
-	O
503	O
were	O
predicted	O
to	O
hybridise	O
with	O
Peroxisome	B-GP
proliferator	I-GP
-	I-GP
activated	I-GP
receptor	I-GP
α	I-GP
(	O
Pparα	B-GP
)	O
(	O
down	O
-	O
regulated	O
)	O
with	O
octamer	O
seeds	O
.	O
Pparα	B-GP
is	O
a	O
major	O
TF	B-GP
that	O
regulates	O
a	O
number	O
of	O
lipid	O
oxidation	O
and	O
metabolism	O
pathways	O
.	O

Moreover	O
,	O
many	O
genes	O
(	O
such	O
as	O
Acad10	B-GP
,	O
Acox3	B-GP
,	O
Cpt2	B-GP
,	O
Dhrs4	B-GP
and	O
Sult5a1	B-GP
)	O
regulated	O
by	O
Pparα	B-GP
were	O
also	O
found	O
down	O
-	O
regulated	O
on	O
mRNA	O
-	O
chips	O
and	O
predicted	O
targets	O
of	O
8	O
miRNAs	O
.	O

These	O
genes	O
are	O
closely	O
engaged	O
with	O
lipid	O
and	O
other	O
metabolic	O
pathways	O
.	O

It	O
has	O
been	O
previously	O
described	O
that	O
Pparα	B-GP
plays	O
a	O
central	O
role	O
in	O
controlling	O
epithelial	O
signals	O
to	O
the	O
interstitium	O
that	O
promote	O
fibrosis	O
via	O
inhibiting	O
the	O
appearance	O
of	O
myofibroblasts	O
as	O
directed	O
by	O
α	B-GP
smooth	I-GP
muscle	I-GP
actins	I-GP
(	O
e	O
.	O
g	O
.,	O
Actn1	B-GP
,	O
Actb	B-GP
and	O
Actg2	B-GP
)	O
and	O
inhibiting	O
the	O
development	O
of	O
interstitial	B-DS
fibrosis	I-DS
[	O
51	O
].	O

The	O
miRNA	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
Pparα	B-GP
and	O
alteration	O
in	O
lipid	O
metabolism	O
pathways	O
could	O
lead	O
to	O
kidney	O
injury	O
and	O
fibrosis	O
as	O
observed	O
in	O
PKD	B-DS
.	O

Furthermore	O
,	O
recent	O
studies	O
identify	O
metabolic	O
pathways	O
and	O
genes	O
regulating	O
them	O
as	O
significantly	O
and	O
independently	O
linked	O
with	O
the	O
progression	O
of	O
CKD	B-DS
[	O
21	O
],	O
[	O
22	O
].	O

Most	O
,	O
but	O
not	O
all	O
types	O
of	O
CKD	B-DS
are	O
complicated	O
by	O
an	O
excessive	O
accumulation	O
and	O
deposition	O
of	O
ECM	O
that	O
progressively	O
leads	O
to	O
destruction	O
of	O
functional	O
nephrons	O
(	O
tubulointerstitial	B-DS
fibrosis	I-DS
).	O

The	O
miRNA	O
-	O
mediated	O
inhibition	O
of	O
E	B-GP
-	I-GP
Box	I-GP
repressors	I-GP
(	O
e	O
.	O
g	O
.,	O
Zeb1	B-GP
)	O
of	O
upstream	O
flanking	O
region	O
of	O
fibrotic	O
genes	O
(	O
such	O
as	O
Fn1	B-GP
and	O
Collagens	B-GP
)	O
under	O
chronic	O
Tgfβ	B-GP
signaling	O
has	O
been	O
demonstrated	O
to	O
drive	O
renal	B-DS
fibrosis	I-DS
[	O
61	O
].	O

Similarly	O
,	O
5	O
miRNAs	O
(	O
e	O
.	O
g	O
.,	O
miR	O
-	O
214	O
,	O
-	O
31	O
and	O
-	O
34a	O
)	O
were	O
predicted	O
to	O
target	O
down	O
-	O
regulated	O
genes	O
such	O
as	O
Glis2	B-GP
and	O
Hnf1α	B-GP
.	O

A	O
small	O
interference	O
in	O
the	O
expression	O
patterns	O
of	O
these	O
inhibitors	O
may	O
result	O
in	O
ECM	O
deposition	O
and	O
could	O
lead	O
to	O
fibrosis	O
as	O
described	O
in	O
previous	O
studies	O
(	O
associated	O
with	O
PKD	B-DS
).	O

For	O
example	O
,	O
a	O
renal	O
-	O
specific	O
inactivation	O
of	O
Hnf1α	B-GP
in	O
mice	B-OG
has	O
been	O
implicated	O
in	O
polycystic	B-DS
kidney	I-DS
disease	I-DS
and	O
shown	O
to	O
mediate	O
the	O
down	O
-	O
regulation	O
of	O
several	O
cystic	B-DS
disease	I-DS
genes	O
localised	O
to	O
primary	O
cilia	O
,	O
including	O
Ift88	B-GP
and	O
Ift122	B-GP
[	O
23	O
].	O

On	O
the	O
other	O
hand	O
,	O
Glis2	B-GP
has	O
been	O
described	O
as	O
a	O
transcriptional	B-GP
repressor	I-GP
for	O
several	O
genes	O
during	O
the	O
expression	O
profiling	O
of	O
kidneys	O
between	O
wild	O
type	O
and	O
Glis2lacZ	O
/	O
lacZ	O
mice	B-OG
[	O
25	O
].	O

Moreover	O
,	O
the	O
development	O
of	O
fibrosis	O
in	O
Glis2lacZ	O
/	O
lacZ	O
mice	B-OG
accompanied	O
by	O
increased	O
synthesis	O
of	O
various	O
ECM	O
components	O
,	O
such	O
as	O
various	O
types	O
of	O
collagen	B-GP
,	O
Ltbp2	B-GP
/	O
4	O
,	O
Fn1	B-GP
and	O
vimentin	B-GP
(	O
Vim	B-GP
)	O
has	O
also	O
been	O
described	O
[	O
25	O
].	O

Furthermore	O
,	O
a	O
comparison	O
of	O
human	B-OG
ADPKD	B-DS
and	O
PKD	B-DS
/	O
Mhm	O
datasets	O
was	O
conducted	O
in	O
which	O
38	O
genes	O
were	O
identified	O
with	O
similar	O
expression	O
patterns	O
(	O
Table	O
S4	O
).	O

These	O
genes	O
are	O
the	O
representatives	O
of	O
ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O
,	O
focal	O
adhesion	O
,	O
cell	O
cycle	O
,	O
proliferation	O
and	O
metabolic	O
pathways	O
.	O

Also	O
,	O
174	O
genes	O
were	O
found	O
with	O
common	O
expression	O
patterns	O
in	O
a	O
comparison	O
with	O
Glis2lacZ	O
/	O
lacZ	O
dataset	O
(	O
Table	O
S8	O
).	O

Moreover	O
,	O
117	O
genes	O
were	O
noticed	O
with	O
similar	O
expression	O
patterns	O
(	O
87	O
up	O
-	O
and	O
30	O
down	O
-	O
regulated	O
),	O
when	O
the	O
dataset	O
of	O
our	O
ADPKD	B-DS
model	O
was	O
compared	O
with	O
the	O
dataset	O
of	O
Hnf1α	B-GP
-	O
deficient	O
mice	B-OG
[	O
24	O
]	O
(	O
Table	O
S8	O
).	O

Taken	O
together	O
,	O
this	O
data	O
suggest	O
a	O
direct	O
transcriptional	O
hierarchy	O
in	O
which	O
Hnf1α	B-GP
and	O
Glis2	B-GP
regulate	O
other	O
cystic	O
genes	O
.	O

It	O
can	O
be	O
assumed	O
that	O
these	O
8	O
up	O
-	O
regulated	O
miRNAs	O
may	O
promote	O
renal	B-DS
fibrosis	I-DS
by	O
targeting	O
the	O
upstream	O
E	O
-	O
Box	O
repressors	O
of	O
up	O
-	O
regulated	O
genes	O
in	O
PKD	B-DS
.	O

Therefore	O
,	O
these	O
discoveries	O
postulate	O
a	O
possibility	O
by	O
which	O
the	O
down	O
-	O
regulation	O
of	O
these	O
8	O
miRNAs	O
may	O
restore	O
the	O
normal	O
expression	O
of	O
the	O
crucial	O
members	O
of	O
the	O
altered	O
pathways	O
(	O
such	O
as	O
focal	O
adhesion	O
,	O
cell	O
cycle	O
,	O
regulation	O
of	O
actin	B-GP
cytoskeleton	O
,	O
ECM	B-GP
-	I-GP
receptor	I-GP
interaction	O
and	O
metabolic	O
pathways	O
).	O

Then	O
,	O
these	O
pathways	O
could	O
be	O
stabilised	O
to	O
their	O
normal	O
function	O
by	O
using	O
antagomirs	O
[	O
62	O
].	O

Conclusions	O

In	O
this	O
study	O
we	O
have	O
performed	O
mRNA	O
and	O
miRNA	O
microarray	O
profiles	O
to	O
explore	O
further	O
epigenetic	O
factors	O
which	O
regulate	O
cystogenesis	O
in	O
PKD	B-DS
.	O

Taken	O
together	O
,	O
our	O
microarray	O
data	O
identified	O
multiple	O
genes	O
that	O
are	O
significantly	O
de	O
-	O
regulated	O
during	O
disease	O
condition	O
.	O

Furthermore	O
,	O
our	O
rat	B-OG
model	O
describes	O
up	O
-	O
regulation	O
of	O
several	O
biological	O
processes	O
and	O
down	O
-	O
regulation	O
of	O
metabolic	O
pathways	O
which	O
are	O
closely	O
associated	O
with	O
cyst	B-DS
formation	O
and	O
expansion	O
.	O

We	O
also	O
observed	O
up	O
-	O
regulation	O
of	O
secreted	O
modulators	O
and	O
integrin	B-GP
receptors	I-GP
subunit	O
.	O

In	O
addition	O
,	O
we	O
also	O
detected	O
many	O
differentially	O
regulated	O
TFs	B-GP
in	O
PKD	B-DS
.	O

Interestingly	O
,	O
the	O
down	O
-	O
regulation	O
of	O
genes	O
associated	O
with	O
ciliary	O
function	O
or	O
renal	B-DS
cystic	I-DS
kidney	I-DS
diseases	I-DS
were	O
also	O
differentially	O
regulated	O
.	O

Moreover	O
,	O
we	O
also	O
contribute	O
8	O
miRNAs	O
to	O
the	O
complex	O
regulatory	O
layers	O
of	O
ADPKD	B-DS
.	O

We	O
predicted	O
that	O
several	O
deregulated	O
genes	O
/	O
pathways	O
are	O
the	O
targets	O
of	O
these	O
8	O
miRNAs	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
these	O
8	O
miRNAs	O
may	O
play	O
a	O
central	O
role	O
in	O
PKD	B-DS
via	O
the	O
down	O
-	O
regulation	O
of	O
key	O
checkpoint	O
genes	O
(	O
inhibitors	O
)	O
of	O
the	O
crucial	O
pathways	O
.	O

These	O
miRNAs	O
should	O
be	O
explored	O
as	O
novel	O
therapeutic	O
targets	O
by	O
performing	O
knockdown	O
/	O
knockout	O
studies	O
using	O
antagomirs	O
that	O
may	O
stabilise	O
the	O
deregulated	O
pathways	O
to	O
their	O
normal	O
function	O
.	O

Moreover	O
,	O
these	O
miRNAs	O
could	O
serve	O
as	O
useful	O
candidates	O
for	O
anti	O
-	O
fibrotic	O
therapies	O
.	O

Supporting	O
Information	O

Significantly	O
regulated	O
genes	O
found	O
in	O
the	O
diseased	O
kidneys	O
of	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
model	O
.	O
This	O
table	O
shows	O
significantly	O
regulated	O
genes	O
on	O
the	O
Affymetrix	O
mRNA	O
microarrays	O
obtained	O
from	O
SAS	O
analysis	O
.	O

A	O
threshold	O
cut	O
-	O
off	O
value	O
was	O
set	O
to	O
1fold	O
change	O
which	O
indicates	O
that	O
the	O
expression	O
of	O
a	O
given	O
gene	O
is	O
uniform	O
in	O
both	O
diseased	O
and	O
control	O
kidneys	O
.	O

The	O
fold	O
change	O
values	O
greater	O
than	O
1	O
indicate	O
up	O
-	O
regulated	O
genes	O
,	O
whereas	O
,	O
the	O
remaining	O
fold	O
change	O
values	O
describe	O
down	O
-	O
regulated	O
genes	O
in	O
diseased	O
kidneys	O
.	O

(	O
XLS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Comparison	O
among	O
PKD	B-DS
/	O
Mhm	O
and	O
PKD1L3	O
/	O
L3	O
datasets	O
.	O
This	O
table	O
shows	O
the	O
common	O
genes	O
obtained	O
by	O
comparing	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
and	O
PKD1L3	O
/	O
L3	O
models	O
.	O

Similar	O
cut	O
-	O
offs	O
were	O
chosen	O
(	O
as	O
described	O
in	O
Table	O
S1	O
)	O
to	O
display	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
among	O
these	O
two	O
datasets	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Comparison	O
between	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
and	O
PKD1	B-GP
−/−	O
datasets	O
.	O
This	O
table	O
shows	O
the	O
common	O
genes	O
obtained	O
by	O
comparing	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
and	O
PKD1	B-GP
−/−	O
models	O
.	O

Similar	O
cut	O
-	O
offs	O
were	O
chosen	O
(	O
as	O
described	O
in	O
Table	O
S1	O
)	O
to	O
display	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
among	O
these	O
two	O
datasets	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Comparison	O
between	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
and	O
human	B-OG
ADPKD	B-DS
datasets	O
.	O
This	O
table	O
shows	O
the	O
common	O
genes	O
obtained	O
by	O
comparing	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
and	O
human	B-OG
datasets	O
.	O

Similar	O
cut	O
-	O
offs	O
were	O
chosen	O
(	O
as	O
described	O
in	O
Table	O
S1	O
)	O
to	O
display	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
among	O
these	O
two	O
datasets	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Common	O
genes	O
obtained	O
between	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
data	O
and	O
Pandey	O
et	O
al	O
dataset	O
.	O
This	O
table	O
shows	O
the	O
common	O
genes	O
obtained	O
by	O
comparing	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
data	O
with	O
the	O
data	O
obtained	O
from	O
Pandey	O
et	O
al	O
[	O
34	O
].	O

Similar	O
cut	O
-	O
offs	O
were	O
chosen	O
(	O
as	O
described	O
in	O
Table	O
S1	O
)	O
to	O
display	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
among	O
these	O
two	O
datasets	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Comparison	O
between	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
and	O
2	O
published	O
studies	O
.	O
This	O
table	O
shows	O
the	O
common	O
genes	O
obtained	O
by	O
comparing	O
PKD	B-DS
/	O
Mhm	O
rat	B-OG
and	O
Hnf1α	B-GP
-	O
deficient	O
[	O
24	O
]	O
and	O
Glis2lacZ	O
/	O
lacZ	O
[	O
25	O
]	O
datasets	O
.	O

Similar	O
cut	O
-	O
offs	O
were	O
chosen	O
(	O
as	O
described	O
in	O
Table	O
S1	O
)	O
to	O
display	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
among	O
these	O
two	O
datasets	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Putative	O
miRNA	O
binding	O
sites	O
of	O
8	O
miRNAs	O
within	O
3	O
,	O
333	O
deregulated	O
genes	O
using	O
miRWalk	O
database	O
.	O
This	O
table	O
shows	O
the	O
putative	O
miRNA	O
binding	O
site	O
predictions	O
obtained	O
from	O
the	O
comparative	O
platform	O
of	O
miRWalk	O
database	O
which	O
integrates	O
the	O
results	O
from	O
9	O
different	O
predictions	O
datasets	O
for	O
comprehensive	O
view	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Significant	O
pathways	O
obtained	O
on	O
8	O
up	O
-	O
regulated	O
miRNAs	O
.	O
This	O
table	O
shows	O
significantly	O
regulated	O
pathways	O
obtained	O
on	O
the	O
target	O
genes	O
of	O
8	O
up	O
-	O
regulated	O
miRNAs	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Information	O
on	O
mRNA	O
and	O
miRNA	O
microarrays	O
quality	O
control	O
analysis	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

